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ABSTRACT
Sphingolipids have over the years, been explored as cancer therapy targets.
FTY720 (Fingolimod, Gilenya) is a sphingosine analogue drug used for the treatment of
multiple sclerosis. FTY720 is phosphorylated by sphingosine kinase 2, to generate PFTY720 to exert its immunosuppressive properties through binding to sphingosine -1
phosphate receptors (S1PRs). FTY720 also exhibits anti-cancer properties. Our previous
studies indicated that FTY720’s anti-cancer property is through induction of necroptosis.
FTY720 directly binds to I2PP2A/SET (Inhibitor 2 of PP2A), consequently activating the
tumor suppressor protein phosphatase 2A (PP2A). The activated PP2A then induces cell
death by activating Receptor-Interacting Protein kinase-1 (RIPK1), involved in
necroptosis signaling. Little is known about the roles of FTY720 in ceramide signaling
and regulation of necroptosis in lung cancer. We therefore, sought to investigate the
mechanisms of FTY720 in inducing necroptosis with regard to ceramide signaling. Our
data indicate that C16-ceramide is crucial for FTY720-induced cell death. Interestingly,
FTY720 does not induce ceramide generation but leads to the formation of specific
ceramide-multi-protein complexes at the plasma membrane involved in plasma
membrane disruption and necroptosis. Here we show D147, N148 and N169 residues in
RIPK1 are important for RIPK1- ceramide binding and cell death. In addition, we show a
novel role for non-muscle Myosin IIA (NMIIA) in trafficking these complexes to the
plasma membrane to promote membrane rupture. We identify RIPK1 L112 and C256
residues as critical for RIPK1-NMIIA interaction. We hereby propose that these novel
1

ceramide complexes form non-selective pores supported by RIPK1 and NMIIA. Our data
suggest that these structures are very specific and are important in the execution of
necroptosis independent of RIPK3 and MLKL. Additionally, preliminary data suggest
that these novel structures can also form in-vivo, without external stimulus, indicating a
possible role in non-pathological conditions.
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CHAPTER ONE:

INTRODUCTION AND LITERATURE
REVIEW
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1. Sphingolipids metabolism
Sphingolipids are a class of structural lipids that are found in membranes. In
addition to their structural role, some sphingolipids have been shown to play key roles in
signal transduction in cells 1. These bioactive sphingolipids like ceramide, sphingosine
and sphingosine 1 phosphate (S1P) have been shown to have roles in cell death, cell
proliferation, cell migration and inflammation. Studies have indicated that ceramide and
S1P mainly play opposing roles in cells. Because of this, there exist a balance between
levels of ceramide and S1P, in what has been referred to as sphingolipid rheostat 2. An
imbalance in this rheostat determines the cell’s fate whether it is towards proliferation or
cell death.
Ceramide, the central molecule in the sphingolipid metabolism is generated in
cells by three main pathways (Figure 1); the de novo synthesis pathway, the salvage
pathway and sphingomyelin breakdown. In de novo synthesis, Serine Pamitoyl
Transferases (SPT/SPTLC), catalyze the condensation of serine and pamitoyl-CoA to
generate 3-ketosphinganine, which is rapidly reduced to dihydrosphingosine by 3ketosphinganine reductase. Through the activity of (dihydro) ceramide synthases
(dihydro-CerSs/CerSs)

the dihydrosphingosine is acylated

to dihydroceramide.

Dihydroceramide is then desaturated by Dihydroceramide desaturase (DES) to yield
ceramide 1, 3.

4

Figure 1 : Ceramide synthesis pathways

Ceramide is generated by multiple pathways including de novo synthesis,
sphingosine recycling (salvage pathway) and breakdown of complex
sphingolipids including sphingomyelin.
There are six known mammalian Ceramide Synthases (CerS1-6) (Table 1).
Different CerSs generate ceramides of varying fatty acid lengths 4. Ceramide Synthase
1(CerS1) is known to generate C18-ceramide. Studies show that C18-ceramide functions
as a pro-death ceramide, accumulation of this ceramide species has been linked to
induction of apoptosis 5, autophagy 2 and mitophagy

6-8

. Ceramide Synthase 2 (CerS2) is

known to catalyze the generation of longer-chain ceramide species C22-24 ceramide 9.
Conversely, C24-ceramide is known to inhibit rather than induce cell death in cancer
cells 10. Ceramide Synthase 3 (CerS3) is mainly localized in testis and tissues and is the
less studied ceramide synthase. CerS3 generates ceramides with very long chain lengths
5

>C26, these very long ceramides are critical for forming the water barrier in the skin 11 .
Ceramide synthase 4 (CerS4), like CerS1, generates C18- ceramide. In addition to C18ceramide, it also produces C20-ceramide. Lack of CerS4 and its products has been
implicated in cell migration and hair growth cycle 12, 13. Ceramide synthase 5 (CerS5) and
ceramide synthase 6 (CerS6) both generate mainly C12, C14, and C16 ceramides

14

.

CerS6 and its product C16 ceramide have been implicated in induction of ER stress

15

.

The role of C16 ceramide varies depending on the cell type and conditions as it has been
shown to have both pro-apoptotic

16

and pro-proliferative 17. Several groups have shown

the significance of the chain length of the fatty acid in ceramide molecules in conferring
their functions. Because of this, it is important for investigators to not generalize the
effect of ceramide as different ceramide species can have opposing roles.

Table 1: Divese biological roles of Ceramide Synthases 1-6
Ceramide synthase
isoform
Ceramide synthase 1
(CerS1)

Ceramide product

Biological Role

C18 ceramide

•
•
•

Induces cancer cell death 5
Decreases tumor growth 18
CerS1 mutant mice have neurological disorders 19

Ceramide synthase 2
(CerS2)

C22-24 ceramide

Ceramide synthase 3
(CerS3)

Ultra-long chain
ceramides >28

•
•
•

C24 ceramide can protect from cell death 20
CerS2 knockout mice exhibit liver damage 21
CerS3 knockout leads to trans-epidermal water loss
leading to death after birth 22

Ceramide synthase 4
(CerS4)
Ceramide synthase 5
(CerS5)

C18 and C20
ceramide
C12, C14, C16
ceramide

•

CerS4 knockout mice exhibit severe alopecia with
alterations in sebaceous glands and sebum contents 12
Implicated in induction of autophagy mediated
hypertrophy of cardiac myocytes 23

Ceramide synthase 6
(CerS6)

C12, C14, C16
ceramide

•
•

•

•
•

Increases cancer cell proliferation 17
Increased expression associates with positives lymph
nodes status 15
Induces chemotherapy mediated apoptosis 10
CerS6 knockout mice exhibit neurological/behavioral
alterations 24

6

Table adapted from Mohammed Dany and Besim Ogretmen, Ceramide induced
mitophagy and tumor suppression 25.
The salvage (recycling) pathway involves the conversion of sphingosine, a
breakdown product of ceramide, back to ceramide. Ceramide is broken down to
sphingosine and a fatty acid through the activity of ceramidases

26

. Sphingosine, a

bioactive molecule can then be phosphorylated by sphingosine kinases, sphingosine
kinase 1 (SK1) and sphingosine kinase 2 (SK2) to generate sphingosine 1 phosphate
(S1P), which is known to be involved in many cellular pathways 27. Excess sphingosine
can also be converted back to ceramide by ceramide synthases, hence the name salvage
pathway 3. It should be noted therefore that inhibition of ceramide synthases not only
inhibits the de novo synthesis pathway, but also the salvage pathway, unlike the
inhibition of serine palmitoyl-CoA transferases, which target only the de novo ceramide
synthesis. S1P can also be metabolized into ethanolamine-1 phosphate and hexadecanal
through the activity of S1P lyase.
Ceramide can also be generated through the breakdown of complex sphingolipids
like glycosphingolipids

28, 29

. Glycosphingolipids have been shown to serve crucial roles

in cells including regulating cell growth, differentiation and neoplastic transformation 30.
Additionally, sphingomyelins can be broken down to generate ceramide and
phosphatidylcholine, through the activity of sphingomyelinases (SMases).
Ceramide can also be modified to generate different sphingolipid molecules.
Ceramide kinase (CERK)

31

or SM synthase (SMS)

32

generate ceramide-1-phosphate

(C1P) and sphingomyelin, respectively (Figure 2). Ceramide is also utilized by
glucosylceramide synthase (GCS) as a precursor for the generation of GlcCer 33. GlcCer
7

is then transported from early Golgi to distal Golgi compartments by four-phosphate
adaptor protein (FAPP2) for the synthesis of glycosphingolipids, determining the lipid
composition of the plasma membrane

34

. Non-vesicular C1P trafficking between

membranes is regulated by a transporter protein GLTPD1 (renamed as C1P transporter
protein, CPTP), which then controls prostaglandin signaling and inflammation 35.
Ceramide is hydrolyzed by ceramidases (CDases) to yield sphingosine, which is
phosphorylated by sphingosine kinase 1 or 2 (SK1 or SK2), to generate sphingosine-1phosphate (S1P). S1P engages with S1P receptors (SIP

1-5/S1PR1-5)

in an

autocrine/paracrine manner for oncogenic signaling 36. S1P is usually rapidly (within 1020 min in cells/tissues) metabolized by S1P phosphatases

37

or S1P lyase

38

, yielding

ethanolamine 1-phosphate and hexadecanol (C16-fatty aldehyde) (Figure. 2).

8

Figure 2 : Sphingolipid metabolism pathway
Ceramide can be formed de novo (pink) or from hydrolysis of sphingomyelin, SM
(blue) or cerebrosides (green). Ceramide can be phosphorylated by ceramide kinase to
yield ceramide 1 phosphate (C1P) or can serve as a substrate for the synthesis of SM or
glycolipids. Ceramide can be metabolized (orange) by ceramidases (CDases) to yield
sphingosine, which in turn is phosphorylated by sphingosine kinase (SK) to generate
sphingosine-1-phosphate, S1P. S1P can be cleared by the action of specific
phosphatases that regenerate sphingosine or by the action of a lyase that cleaves S1P
into ethanolamine-1-phosphate and a C16-fatty aldehyde. C1PP, ceramide 1-phosphate
phosphatase; CRS, cerebrosidase; CK, ceramide kinase; CS, ceramide synthase; DAG,
diacylglycerol; DES, dihydroceramide desaturase; GCS, glucosylceramide synthase;
PC, phosphatidylcholine; S1PP, S1P phosphatase; SMS, sphingomyelin synthase;
SMase, sphingomyelinase; SPT, serine palmitoyl transferase.

Figure adapted from Besim Ogretmen and Yusuf Hannun,

Biologically active

sphingolipids in cancer pathogenesis and treatment 3.
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2. Ceramide in programmed cell death and tumor suppression
Induction of cell programmed cell death in cancer cells has been applied as one
means to induce tumor suppression. Some of the programmed cell death implicated in
tumor suppression include apoptosis, autophagy and programmed necrosis (necroptosis)
39

. Addition of exogenous ceramide analogs and/or induction of endogenous ceramide

accumulation have been implicated in the induction of caspase dependent as well as
caspase independent programmed cell death. It has been shown that cells generate
ceramide and sphingosine during cytotoxic stress.

a) Apoptosis
Apoptosis is a form of programmed cell death involving the activation of cysteine
proteases known as caspases

40

. Cellular phenotypes known for cells undergoing

apoptosis include DNA fragmentation, cell shrinkage, chromatin condensation and
membrane blebbing. Induction of apoptosis is well studied in cancer as a regulated form
of clearing cancerous cells without triggering the inflammatory response.
Ceramide has been implicated in apoptosis induction in cancer cells. Ceramide
was initially reported to induce apoptosis in leukemia cells

41

. Since this initial report

ceramide-mediated apoptosis has been intensively investigated and reported in many
other different cancer types 1. C2 and C16-ceramides have been shown to form large
channels (ceramide channels) in mitochondrial membranes. Formation of these types of
channels promoted mitochondrial outer membrane permeabilization (MOMP) and
apoptosis

42, 43

. Interestingly, very long ceramides and dihydroceramides have been
10

shown to greatly destabilize these channels

44, 45

, showing a possible mechanism of how

these channels and ceramide-mediated apoptosis are regulated. C16-ceramide, generated
by CerS6 has also been shown to be increased in TRAIL (tumor necrosis factor-related
apoptosis-inducing ligand) induced apoptosis

46

. This study found that SW620 colon

cancer cells, which were resistant to TRAIL, had low levels of CerS6 and elevation of
this enzyme increased their sensitivity to TRAIL, leading to apoptosis.
Resisting cell death is one of the hallmarks of cancer

47

and cancer cells have

evolved ways to evade apoptosis. One known way is by modulating the sphingolipid
rheostat, leading to decreased ceramide and increased S1P generation, which has been
associated with proliferation (reviewed in

48

). Manipulation of the sphingolipid

metabolism pathway to increase ceramide generation and promote apoptosis has been one
way to induce cell killing in apoptosis- resistant cancer cells.

11

b) Autophagy
Autophagy, from the Greek word meaning, “self-eating” is a cellular process
whereby the cell digests some of its organelles, during starvation conditions to provide
nutrients to itself

49

. In some instances, autophagy has been shown to promote caspase

independent cell death, also known as lethal autophagy.
As in the case with apoptosis, ceramide has also been shown to play critical
signaling roles in autophagy. Accumulation of ceramide induces both types of autophagy
25, 50, 51

. In lethal autophagy, ceramide leads to autophagy by modulating the expression of

autophagic proteins like Beclin-1

52

. In another study, ceramide was shown to induce

autophagy in amino acids deprivation through mTOR suppression 2. Additionally,
dihydroceramide has also been shown to induce autophagy. In glioma cells,
Tetrahydrocannabinol

(THC,

the

active

component

of

marijuana)

triggered

dihydroceramide accumulation in the endoplasmic reticulum (ER), promoting
autophagosomal and lysosomal membrane permeabilization, leading to cathepsin release
and apoptosis

53

. Expectedly, sphingomyelin accumulation, by silencing SMPD1, has

been correlated with aggregation of elongated and unclosed autophagic membranes with
reduced association of ATG9A in cancer cells 54 (Figure 3).

12

Figure 3 : Ceramide involvement in cell death
Ceramide has been implicated in multiple cell death pathways in cancer. Ceramide can
induce apoptosis through caspase activation, necroptosis through PP2A and RIPK1
activation and mitophagy through targeting autophagolysosomes to the targeted
organelles or by macro-autophagy by promoting maturation of autophagosomes.

13

Ceramide has also been implicated in a more organelle specific type of autophagy
known as mitophagy. Mitophagy is the digestion of cell’s mitochondria to provide
nutrients to the cell during starvation or in some instances to induce cell death

55

.

Accumulation of C18-ceramide, exogenously added or induced through CerS1 activation,
was shown to specifically accumulate in the mitochondria and propagate mitophagy
through tethering of LC3B to the mitochondria in head and neck (HN) cancer cells

8

(Figure 3). This phenomenon has also been observed in AML (acute myeloid leukemia)
cells. Interestingly, the addition of exogenous C18 pyridinium ceramide (LCL461),
which is specifically targeted to the mitochondria because of the positively charged
pyridinium ring, induced mitophagy and this overcame FLT-3 mediated chemoresistance
7

. It was also shown that ceramide-dependent lethal mitophagy was regulated by the

activation of DRP1 and mitochondrial fission, involving PKA inhibition and decreased
phosphorylation of DRP1 at S637 in FLT3+ AML cells 7. In addition, HPV/E7 protein
has been shown to confer its sensitivity to chemotherapy through increased C18-ceramide
levels which promotes mitophagy in HN cancer cells 6.

c) Necroptosis
Necroptosis is a form of programmed cell death that involves the activity of
receptor interacting proteins (RIPKs) (Figure 4). Necroptosis has been shown to play a
role in both physiological and pathological settings

56

. In cells, RIPK1 is typically poly

ubiquitinitated via K63-linked ubiquitin chains by CIAPs (cytoplasmic inhibitors of
apoptosis) and signals for NFkB activation

57

. In canonical necroptosis, activation of
14

death receptors leads to activation of RIPK1 through de-ubiquitination by CYLD 58, Deubiquitination of RIPK1 increases its affinity for RIPK3 and other adaptor proteins to
signal for necroptosis as opposed to pro-survival NFkB signaling 57-60 . Activated RIPK1
recruits and phosphorylates RIPK3. Phosphorylated RIPK3 (active) then phosphorylates
MLKL (mixed-lineage Kinase domain-like) a pseudo kinase. Phosphorylated MLKL
oligomerizes and the oligomers translocate to the plasma membrane where they form
pores and lead to plasma membrane rupture 61, 62, 63.

15

Figure 4 : Necroptosis signaling
Activation of RIPK1 from extracellular and intracellular stimuli leads to activation of
RIPK3 followed by recruitment and activation of MLKL and plasma membrane
disintegration.

Figure was taken from Meng et.al, Necroptosis in tumorigenesis, activation of anti-tumor
immunity, and cancer therapy 64.

16

Ceramide has been shown to be involved in necroptosis in lung and ovarian
cancer. In lung cancer, studies indicate that C18-ceramide binds I2PP2A/SET (Figure 3),
an endogenous inhibitor of tumor suppressor PP2A, leading to the activation of PP2A,
which leads to RIPK1 activation, through unknown mechanism

65

. However, the exact

mechanisms of this activation remain unclear. In ovarian cancer, exogenous ceramide,
through ceramide nanoliposomes was shown to activate MLKL 66. U937 lymphoma cells
treated with a combination of TNFa and ZVAD underwent necroptosis and exhibited a
significant increase in the levels of C16-ceramide, indicating a role of this ceramide
species in necroptotic signaling 67.
Although in this dissertation study, I focused on the role of ceramide in
necroptosis, it is important to note that, in addition to programmed cell death, ceramide
has also been implicated in other cellular mechanisms that lead to tumor suppression.
These include ER stress and cell cycle arrest, discussed below.

d) Ceramide and ER Stress
Induction of ceramide-associated ER stress was reported as an upstream regulator
of autophagy

68

. Melanoma differentiation associated gene-7 (mda-7) regulated IL-24

induced ER stress, leading to ceramide-mediated lethal autophagy in glioblastoma cells
69

. Methotrexate-induced folate stress in lung cancer cells increased the formation of ER

stress aggregates with CerS6 accumulation, which was associated with the activation of
p53 70.

17

e) Ceramide and cell cycle arrest
Ceramide’s inhibition of cancer progression has also been shown to occur through
cell cycle arrest. In MOLT4 leukemia cells, ceramide and its metabolite sphingosine led
to the dephosphorylation Retinoblastoma protein (Rb), which led to cell cycle rest in
Go/G1 and growth suppression 71. Exogenously added C6 ceramide was shown to arrest
rhabdomyosarcoma (RMS) cells in G2 phase and eventual apoptosis of these cells

72

.

Additionally, exogenously added C2 ceramide also induced cell cycle arrest in Bel7402
hepatocarcinoma cells 73.

3. Ceramide generation in chemotherapy/radiation-mediated tumor suppression
CerS-generated ceramide was linked to daunorubicin-induced apoptosis in various
cancer cells 74. Vorinostat and sorafenib combination was efficacious in the inhibition of
gastrointestinal tumor and pancreatic tumor-derived xenograft growth in mice. The
mechanism involved activation of CD95 through the generation of Ca+2 and CerS6dependent ceramide, leading to PP2A and ROS signaling 75. In a phase II clinical trial in
patients with recurrent HN cancers, elevation of serum C18-ceramide was significantly
associated with improved response to gemcitabine plus doxorubicin combination therapy,
which induced CerS1/C18-ceramide 76.
In intestinal stem cells, Ataxia telangiectasia (ATM) kinase regulates target
switching to escalating doses of radiation via activation of ceramide synthesis, without
affecting microvascular response

77

. Interestingly, neutralizing ceramide signaling by

anti-ceramide antibody prevented gastrointestinal damage in response to radiation,
relieving gastrointestinal syndrome mortality 78. Measurement of plasma ceramide levels
18

during the treatment of 35 patients with hypo-fractionated stereotactic body radiation
79

therapy showed that elevated total ceramide was associated with positive response

.

Moreover, ABC294640, a pharmacological inhibitor of SK2, which was shown to also
inhibit DES, resulting in the accumulation of dihydro-ceramides 80, has been successfully
tested in a phase I clinical trial for the treatment of patients with advanced solid tumors
81

. Thus, these data suggest that increased (dihydro) ceramide generation in cancer cells

in response to chemotherapy or radiation play important roles in tumor suppression.

4. Ceramide metabolism in tumor immunology and immunotherapy
In addition to its roles in chemo/radiotherapy, ceramide signaling is implicated in
the regulation of tumor immunology and immunotherapy. C16-Ceramide inhibited the
growth of myeloid derived suppressor cells (MDSCs) by activating lysosomal cathepsin
B/D and inducing autophagy in these cells

82

. Induction of autophagy and ER stress in

MDSCs enhanced cytotoxic T cell lymphocyte function for tumor suppression

82

. In

Gaucher’s disease patients, who are susceptible to myeloma, clonal immunoglobulin was
reactive against lyso-glucosylceramide, which is highly elevated in these patients due to
deficiency in glucocerebrosidase

83

. These data suggested that lyso-glucosylceramide

might be involved in the origin of myeloma and/or Gaucher’s disease-associated
gammopathy 83. Interestingly, in Gaucher’s disease complement signaling via C5a/C5aR1
induced GlcCer accumulation and tissue inflammation

84

. Recently, Sofi et.al

demonstrated that CerS6/C16-ceramide enhanced T-cell response to alloantigens during
allogeneic hematopoietic cell transplantation (allo-HCT), an effective immunotherapy for
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various hematologic malignancies

85

. The data revealed that genetic loss of CerS6

prevented graft versus host disease (GVHD), a major toxicity limiting the anti-leukemic
efficacy of allo-HCT

85

. Thus, these data suggest that ceramide metabolism/signaling

plays key roles in the regulation of anti-cancer immunotherapy.

5. Targeting sphingolipid metabolism and signaling for cancer therapy.
Given the importance of sphingolipids in promoting cancer progression or
inhibition, sphingolipids have become great targets for cancer therapy. Highly soluble
pyridinium-ceramides, selectively accumulating in cancer cells’ mitochondria, induced
lethal mitophagy

7, 8

and tumor suppression in HN, AML and prostate cancers

86, 87

.

Inhibition of survivin by nanoliposomal ceramide (NLC) resulted in complete remission
of the natural killer type of aggressive large granular lymphocytic leukemia

88

. NLC is

now tested in a phase I clinical trial for the treatment of patients with advanced solid
tumors (NCT02834611).

The table below shows some of the anticancer that target the sphingolipid
metabolism that have been developed and being studied for clinical purposes.
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Table 2: List of anticancer drugs targeting sphingolipid metabolism
Name
Target or activity
Ceramide inducers and analogues
C8
CPC
(C8- DES
cyclopropenylceramide)
CHC
(3-chloro
8b- CERT: ceramide trafficking,
sphingomyelin synthesis
hydroxycarapin-3,8-hemiacetal)
NVP-231
CERK
LCL 521 and LCL 204
Pyridinium ceramide (LCL-124
and LCL-461)
Nanoliposomal ceramide
Surviving, MLKL
Targets of S1P metabolism and signaling
FTY720
S1PR1;I2PP2A
JTE013
AB1
SK1-I
PF543
VPC03090
Sphingomab (sonepcizumab)
ABC294640

S1PR2
S1PR2
SK1
SK1
S1PR1;S1PR3
S1P
SK2; DES

Stage of Development
Preclinical 89
Preclinical 90
Preclinical 91
Preclinical 92-94
Preclinical 86, 87
Preclinical 66, 88
FDA-approved for
sclerosis 65, 95-97
Preclinical 98
Preclinical 99
Preclinical 100
Preclinical 101
Preclinical 102
Phase II 103
Phase 1b and II 81, 104

multiple

Modified table adapted from Besim Ogretmen, Sphingolipid metabolism in cancer
signaling and therapy 1.

6. FTY720
The

US

Food

and

Drug

Administration

(FDA)

approved

(Fingolimod/Gilenya, Novartis, Inc), for the treatment of relapsing MS

FTY720
105, 106

.

Mechanistically, FTY720 is phosphorylated in cells by one of the two sphingosine
kinases, sphingosine kinase 2 (SK2)

105, 106

to generate P-FTY720. P-FTY720 is
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trafficked to outside the cell by SNSP2

107

, the same transporter that traffics S1P. On the

plasma membrane P-FTY720 binds S1P receptors (S1PRs) where it acts as a functional
antagonist (Figure 5). There are five S1PRs (S1PR1-5), and P-FTY720 binds all of them
except S1PR2

108

. Binding of P-FTY720 to the S1PRs leads to their internalization and

degradation. Degradation of S1PRs after P-FTY720 binding disrupts the S1P gradient,
usually maintained to allow T cells egress from lymph nodes to the bloodstream, hence
conferring its immune suppressive property.

Figure 5 : FTY720 signaling in multiple sclerosis and cancer
To induce immune suppression, important for multiple sclerosis, FTY720 is
phosphorylated by SK2 to generate P-FTY720 which binds S1PRs and leads to their
degradation. In cancer, the prodrug, FTY720 (without phosphorylation) induces different
types of cell death depending on cell type and other conditions.
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FTY720 (prodrug) also exhibited tumor suppression via S1PR-dependent
receptor-independent

65

109

and

mechanisms (Figure 5). Receptor-independent mechanism

involves inducing necroptosis via inhibition of onco-protein SET and activation of tumor
suppressor PP2A signaling in various cancer types, including lung, oral and colon cancers
65, 110, 111

. Another tumor-suppressor mechanism results in inhibition of CML stem cell

proliferation/expansion, reversing CML drug resistance 97. FTY720 has also been shown
to induce apoptosis in multiple myeloma through down regulation of anti-apoptotic
protein, MCL-1

112

and activation of caspases 8, 9 and 3

113

. Intriguingly, FTY720

induced apoptosis even in cells that were known to be resistant to common
chemotherapeutic agents

113

. In glioblastoma, FTY720 was shown to induce tumor

suppression by activating more than one type of cell death 114, demonstrating the diversity
in the different mechanisms of cell death induced by FTY720 in different cell types.
These data suggest that sphingolipid metabolism and signaling present a valuable target
for cancer therapy. Although cancer cell death activity of FTY720 requires micro molar
(10-20 µM) concentrations to be effective in cell culture studies, tumor suppression in
human lung cancer xenografts grown in mice was achieved using physiologically
relevant concentration (3 mg/kg/day) via induction of necroptosis in vivo 65.
FTY720 has also been shown to either increase cancer cells’ sensitivity to
chemotherapeutic agents, or radiation, when used in combination with other
chemotherapeutic agents in multiple cell lines. In multiple myeloma, when used together
with bortezomib 112, dexamethasone, or anti-Fas antibody 113 the cells exhibited increased
apoptosis. When used in combination with Cisplatin, FTY720 was shown to induce
autophagy-related apoptosis in non-small cell lung carcinoma, sensitizing cells initially
23

resistant to cisplatin

115

. In triple negative breast cancer model, FTY720 was used in

combination with an EGFR inhibitor, leading to tumor suppression 116 and also sensitized
breast cancer cells to radiation 117.
In addition, FTY720 has been used as a lead compound in developing inhibitors
for specific ceramide synthases: ST1060 inhibited CerS2, ST1072 inhibited CerS4 and
CerS6, while ST1058/1074 inhibited CerS2 and CerS4

118

. These chemicals provide

valuable preclinical tools to distinctly regulate various CerS enzymes and their specific
ceramide products in different cancer models. In fact, inhibition of CerS6 by ST1072
reduced T cell activation in response to allogeneic stimulation in mouse and human T
cells, preventing GVHD toxicity during allo-HCT for anti-leukemia therapy 85. Inhibition
of GCS by PDMP (D-thereo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol)
sensitized CML cells expressing mutant Bcr-Abl (T315I) to tyrosine kinase inhibitors by
inducing glycogen synthase kinase-3 (GSK-3)-dependent apoptosis

119

. Overall these

studies show the potential of FTY720 and its analogues as chemotherapeutic agents, as
stand-alone or in combination with other agents.

7. FTY720 modulation of sphingolipid metabolism
FTY720 has been shown to modulate different sphingolipid molecules by
interacting with the enzymes of the sphingolipid pathways to induce cell death. Multiple
studies have shown, in colitis and cancer models, that FTY720 reduced the expression of
SK1

109, 120

. Another study on the contrary, found that FTY720 also inhibited S1P lyase

121

, the enzyme known to cleave S1P. This suggested FTY720 was cleaved and

dephosphorylated by other enzymes. This led to further studies that identified several
24

enzymes that metabolize FTY720. CYP4F hydroxylates and oxidizes FTY720 for
elimination

122

, while Lipid phosphate phosphatase, LPP3

123

124

and LPP1a

dephosphorylate P-FTY720. Moreover, FTY720 has been shown to inhibit ceramide
synthases and lead to dihydrosphingosine 1-phosphate accumulation in human lung
endothelial cells

125

. Accumulation of dihydrosphingosine-1 phosphate shows this

inhibition is of the de-novo synthesis pathway of ceramide generation. Interestingly,
another study by Lahiri, S. et. al., found that FTY720 could also modulate Ceramide
syntheses activity via a mixture of uncompetitive and noncompetitive inhibition

126

. As

before-mentioned, ceramide accumulation in cells has been implicated in caspase
independent cell death

7, 25

including necroptosis

127

and mitophagy

128

. However,

whether FTY720 has any implication for ceramide generation and/or signaling during
necroptosis in lung cancer is a question that still remains unanswered.

8. Ceramide signaling in stem cells
Sphingolipids have also been implicated in normal and cancer stem cells biological
activities. In Glioblastoma, S1P signaling was found to be crucial for maintenance of
stemness in glioblastoma cells

129

. In non-pathological context, ceramide and S1P have

been shown to play key roles in embryogenesis by regulating stem cell differentiation 130,
131

. In one study, ceramide generated from neutral sphingomyelinase and de novo

synthesis propagated primary ciliogenesis and promoted differentiation in embryonic
stem cells and neuroprogenitors

132

. This study showed that inhibition of ceramide

generation significantly reduced ciliogenesis, which was restored with addition of
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exogenous ceramide

132

. These studies further illustrate the key roles played by

sphingolipids in both physiological and pathological conditions.

9. Ceramide signaling in Drosophila melanogaster
To study ceramide signaling in-vivo, Drosophila melanogaster (D. melanogaster)
ovaries are a great model as they contain different types of stem cells

133

. In D.

melanogaster, ovary development (oogenesis) begins with the formation of cyst of
interconnected germ cells, produced by germline stem cells, enveloped by somatic
follicle cells

134

. Oogenesis in insect cells requires a complex mechanism for

differentiation of germ line and somatic cells

135

. The Drosophila ovary contains three

types of stem cell populations, germline stem cells (GSC), somatic stem cells (SCC) and
escort stem cells (ESC), which are contained in a well-defined anatomical structure called
germarium 136-138. Thus, insect ovaries present an ideal model to study the roles of various
mechanisms in the regulation of stem cell development and signaling. As opposed to
mammals, D. melanogaster has only one isoform of ceramide synthase, known as
schlank

139

. Predictably, knocking out schlank in D. melanogaster is lethal

139

,

emphasizing the importance of ceramide and sphingolipids signaling in embryogenesis
and

development.
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Figure 6 : Drosophila melanogaster oogenesis

A. Drosophila oogenesis is fueled by the activity of germline stem cells. The Drosophila
ovary is composed of 14–16 ovarioles, each harboring a germarium and older follicles that
progress through 14 distinct stages of development. B. shows the germarium. The germarium
contains germline stem cells (GSCs; pink) that are juxtaposed to cap cells, the major cellular
component of the somatic niche (purple), and a subset of escort cells (blue). GSCs divide to
form daughter cells (cystoblasts), which divide four additional times to form 16-cell germline
cysts (peach) composed of nurse cells and an oocyte. Follicle stem cells (FSC; dark green)
divide to form pre-follicle cells, which surround the 16-cell germline cyst, and pinch away
from the germarium, forming a follicle. Pre-follicle cells give rise to a variety of specialized
follicle cells (fc; green) that reside in an epithelial monolayer around each cyst.

This figure was adapted from Abels et. al., A Genetic Mosaic Screen Reveals
Ecdysone-Responsive Genes Regulating Drosophila Oogenesis 140.
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Given the importance of ceramide in programmed cell death tumor suppression and
with the knowledge that FTY720 induces RIPK3-MLKL independent necroptosis in lung
cancer cells, in this study, I sought to investigate if FTY720- induced necroptosis was
ceramide dependent. It is important to note that FTY720-induced necroptosis in lung
cancer cells differs from the canonical necroptosis, in that it is RIPK3 and MLKL
dependent. This leaves a gap in knowledge of how the plasma membrane integrity is
compromised during this type of necroptosis. FTY720 has been shown to modulate
ceramide signaling and this could also be occurring during the induction of necroptosis.
Putting this knowledge together, I investigated the potential of ceramide modulation by
FTY720 to affect the plasma membrane integrity, independent of MLKL. Additionally, I
investigate the role of ceramide-enriched macrodomains in a non-pathological context,
using drosophila melanogaster as my model.
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CHAPTER TWO:

MATERIALS AND METHODS
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Cell lines and Reagents
A549, and H1341 human lung cancer cells were grown in DMEM containing 10% FBS
(Cellgro) and 1% penicillin/streptomycin (Cellgro), WT MEFs and NHFL were grown in
DMEM with 10% FBS and 1% Pen/Strep. Cells were treated with the following reagents:
FTY720, P-FTY720, NBD-FTY720, Latrunculin A (Cayman Chemical Company), OSU2S (was a gift from Dr. Chen, Ohio State University), Myriocin (Sigma), LPA (Santa
Cruz Biotechnology), Brefeldin A (Sigma), AZ10606120, ARRY 520, K858, Ciliobrevin
(Tocris), Blebbistatin (Selleckchem), Necrosulfonamide, NSA (EMD Millipore),
Sphingosine, (Avanti Polar Lipids), Fumonisin B1, FB1 (Enzo) Biotinylated C6-ceramide
(Echelon Biosciences). Full length recombinant RIPK1 was purchased from Origene. The
antibodies used were Ceramide MB154 (Enzo), cholesterol (US Biological) RIP-1 (Cell
Signaling), non-muscle Myosin IIA, b-Actin (Sigma), GM130, Calnexin, Eaa1, CD63,
Caveolin-1, CerS5, CerS6, Acid Ceramidase (Santa Cruz Biotechnology). Nanogold
Gold- antibody Conjugates, (mouse and Rabbit) were from Nanoprobes. a1B1
(University of Iowa, Developmental Studies Hybridoma Bank). Rhodamine phalloidin
and YO-PRO-1 were purchased from Life sciences (Thermo Fisher Scientific).
DUOLINK Proximity Ligation Kit and streptavidin-coated 96 well plates were purchased
from Sigma.

Plasmid constructs and shRNAs
The shRNA lentiviral plasmids were purchased from sigma-Aldrich. The TRC numbers
and sequences are as follows: shMYH9 (gene ID: 4627), TRCN0000285480, sequence:
CCGGGCCAAGCTCAAGAACAAGCATCTCGAGATGCTTGTTCTTGAGCTTGGC
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TTTTTG,

shRIPK1,

(gene

ID

8737),

TRCN0000200006,

sequence:

CCGGCGGAACAGATTCTGGTGTCTTCTCGAGAAGACACCAGAATCTGTTCCG
TTTTTTG,

shCerS1

(gene

id:

10715),

TRCN0000168211,

sequence:

CCGGCTACTTCTTCTTCAATGCGCTCTCGAGAGCGCATTGAAGAAGAAGTAGT
TTTTTG,

shCers2

(gene

id:

29956),

TRCN000276376,

sequence:

CCGGCCTGCCTTCTTTGGCTATTACCTCGAGGTAATAGCCAAAGAAGGCAGG
TTTTTG,

shCerS4

(gene

id:

204219)

TRCN0000016986,

sequence:

CCGGGTTACATGATTCCTCTGACTACTCGAGTAGTCAGAGGAATCATGTAACT
TTTT,

shCerS5

(gene

id:

91012)

TRCN0000022221,

sequence:

CCGGGTGGGCTTTATCACTATTATACTCGAGTATAATAGTGATAAAGCCCACT
TTTT,

shCerS6

(gene

id:

253782)

TRCN0000344342,

sequence:

CCGGGAACTGCTTCTGGTCTTACTTCTCGAGAAGTAAGACCAGAAGCAGTTCT
TTTTG,

shSPT1

(gene

ID:10558)

TRCN0000303825

sequence:

CCGGGCTATTCCTGCTTACTCTAAACTCGAGTTTAGAGTAAGCAGGAATAGCT
TTTTG,

shSPT2

(gene

ID:

9517)

TRCN0000286903,

sequence:

CCGGGCTCATACCAAAGAAATACTTCTCGAGAAGTATTTCTTTGGTATGAGCT
TTTTG,

shSPT3

(gene

ID:

55304)

TRCN0000136363,

sequence:

CCGGCAAACATCTCATGGGCAACTACTCGAGTAGTTGCCCATGAGATGTTTGT
TTTTTG,

shSMPD3/nSMase2

(gene

ID:

55512)

TRCN0000048943

sequence:CCGGCCCAACAAGTGTAACGACGATCTCGAGATCGTCGTTACACTTG
TTGGGTTTTTG, SMPD4/nSMase 3 (gene ID: 55627) TRCN0000245620, sequence:
CCGGCCTGAAAGCTGACTCTATAAACTCGAGTTTATAGAGTCAGCTTTCAGGT
TTTTG,

shSK2

(gene

ID:

56848)

TRCN0000036973,

sequence:
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CCGGCTACTTCTGCATCTACACCTACTCGAGTAGGTGTAGATGCAGAAGTAGT
TTTTG,

RIPK3

(gene

ID:

11035)

TRCN0000002261,

sequence:

CCGGCTACAGCTTCGGGATCCTAATCTCGAGATTAGGATCCCGAAGCTGTAG
TTTTT, pMD2.G (Addgene plasmid #12259) and pCMV-psPAX2 (Addgene plasmid #
12260) were gifts from Dr. Didier Trono. Non-targeting shRNA (shSCR) was used as
control.

Stable shRNA knockdown studies
CerS1, CerS2, CerS4, CerS5, CerS6, SPT1, 2, 3, nSMase 1, 2, 3, SK2, RIPK1, RIPK3,
MYH9 and non-targeting shRNA containing plasmids (purchased form the MUSC
shRNA shared Technology Resource) were co-transfected in HEK293 packaging cells
with together with pCMV-psPAX2 and pMD2.G plasmids to generate lentiviral particles.
The lentiviral particles were collected after 48Hrs. These were added to H1341/A549
cells, together with 10µg/mL polybrene. After 48 hours, the lentiviral particles were
removed and cells were selected for approximately 14 days with 2µg/mL puromycin.

Site Directed Mutagenesis
RIPK1 D147A, N148A, N169A, N186A, L112A, C256A, R258A, L293A, E295A
mutants were generated using Q5 site-directed mutagenesis kit (New England Biolabs)
per manufacturer’s instructions. Primers were designed using NEBaseChanger (New
England Biolabs) and are listed in the table below.

32

Table 3: List of Primers used to generate RIPK1 mutants
RIPK1

Forward sequence (5’-3’)

Reverse sequence (5’-3’)

mutant
D147A

TATCCTTGTTGCTAATGACTTCCAC

TTTTCAGGCTTCAGGTCC

N148A

CCTTGTTGATGCTGACTTCCACATTAAG

ATATTTTCAGGCTTCAGG

N169A

GAGCAAACTGGCTAATGAAGAGCACAATG

CACATCTTAAAGGAGGCAAG

N186A

CGCTAAGAAGGCTGGCGGCACCC

GTGCCGTCCACTTCCCTC

L112A

GAGTACTCCGGCTTCTGTAAAAGGAAGG

ATCTCGGCTTTCAGCACG

C256A

CACTGAGTACGCCCCAAGAGAAATTATC

ATGTCATCCACATCTGGC

R258A

GTACTGCCCAGCAGAAATTATCAGTC

TCAGTGATGTCATCCACATC

L293A

TTTAAGTCAAGCAGAAGAAAGTGTAGAAG

TAAAAAGGCCTAAATTTTTCTTC

E295A

TCAATTAGAAGCAAGTGTAGAAGAG

CTTAAATAAAAAGGCCTAAATTTTTC

Immunofluorescence Labeling
Cultured cells were incubated the respective treatment, washed two times with 1X PBS,
fixed with pre-warmed 4% paraformaldehyde (PFA) for 15 minutes at room temperature,
permeabilized for 10 minutes with 0.01% Triton X-100, blocked for 20 minutes with 1%
BSA before incubation with primary antibody in blocking solution overnight at 4°C. The
following day the cells were incubated with secondary antibody (Alexa fluor-488 antimouse) and Rhodamine phalloidin. The coverslips were mounted on slides with a drop of
Prolong anti-fade reagent (Invitrogen), and sealed with nail polish. Labeling patterns
were observed using Olympus FV10i Laser Scanning confocal microscope. Images were
analyzed by Flouview Fv10i software. Ceramidosomes quantification was performed
using Fiji (ImageJ).
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Proximity Ligation Assay
Proximity ligation assays were performed using Duolink in situ red kit (Olink
Biosciences, Sigma) per manufacturer’s instructions. Antibodies were used at 1:100
dilution, probed overnight at 4° C. Images were analyzed as described previously 141.

Co-Immunoprecipitation and Western blotting
For immunoprecipitation, cells were grown to 70% confluency, treated with FTY720 or
vehicle, cells were rinsed with cold 1X PBS, scrapped off and lysed in Pierce IP lysis
buffer (non-denaturing) with protease inhibitor cocktail and phosphatase inhibitor.
Immunoprecipitation was done with RIPK1 or Myosin IIA antibody. Lysates were
precleared with 40µl of protein A/G beads and control IgG and incubated in a rotatory
shaker for 1 hr at 4°C. Samples were centrifuged at 2,000Xg for 5 minutes. The
supernatant was collected and incubated with the respective antibody at 4°C for 1 hr
before adding 40µl agarose beads and rotating overnight. The following day, samples
were centrifuged at 2,000 g for 5 minutes; the beads were washed with cold 1X PBS four
times, followed by the addition of 2X loading dye. The samples were boiled using a
heating block before western blotting. For assays cells were homogenized in RIPA buffer
(25mM Tris-HCl pH7.4, 150mM NaCl, 1% TritonX-100,1% sodium deoxycholate,
EDTA (20µl of 0.5M stock) including protease inhibitor cocktail using a gauge (26.5G)
syringe five times, incubated for 20 minutes on ice. The samples were centrifuged at
12,000Xg for 15 minutes at 4ºC. The supernatant was collected and proteins were
quantified with Bradford method. 4X loading dye was added to sample and boiled using a
34

heating block at 95ºC for 5 minutes before loading. SDS gradient gels 4%-20% were used
to run the samples with Bio Rad Criterion apparatus, followed by semi-dry transfer onto
PVDF membrane. Blocking was done with 5% milk in 0.1% PBST. Primary antibodies
were used at 1:2000 dilution overnight at 4ºC. Proteins were analyzed by Western
blotting using the following antibodies: the rabbit RIPK1 (Cell signaling), β-actin
(Sigma, St. Louis, MO), anti-GFP (Santa Cruz), Non-muscle Myosin IIA (Sigma).

Quantitative RT-PCR
RNA was extracted from cell pellets using RNeasy kit (Qiagen) per the manufacturer’s
instructions. cDNA was generated using equal amounts of RNA from each sample and
iScript cDNA synthesis kit (Bio-Rad) per manufacturer’s instructions. The thermal cycler
protocol used was as follows; Priming (5 min at 25°C) followed by Reverse transcription
(20 min at 46°C) and RT inactivation (1 min at 95°C). Reactions were carried out using
SsoAdvance universal probes mix (Bio-Rad) and TaqMan primer probes (ThermoFisher
Scientific) in a BioRad CFX96 RealTime system. The thermal cycling protocol used was
as follows: Polymerase activation and DNA denaturation at 95°C for 30 sec, followed by
40 amplification cycles (denaturation at 95°C for 10 sec and annealing/extension and
plate read at 60°C for 30 sec).

Membrane permeability/Dead cell apoptosis kit with YO-PRO-1 and PI
Cells were cultured to 70-80% confluency, and then treated with 20µM FTY720 or
vehicle. The cells were collected by scrapping off the dishes, rinsed with cold 1X PBS,
resuspended in 1 mL cold PBS dyes were then added at 1µl/mL concentration. The
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samples were kept on ice for 20-30 minutes before analysis by flow cytometry on
LSRFortessa/X-20. For live cell imaging, cells were treated with 20µM FTY720 or
vehicle and incubated with the dyes (1µl/mL). Pictures were taken every 30 minutes for a
period of 3 hrs. For the RIPK1 mutants, membrane permeability was analyzed by
propidium iodide only in GFP positive cells.

Trypan blue exclusion assay
Cells were seeded in 6-well plates and allowed to adhere for 20 hours. Treatment was
with 20µM FTY720 in DMSO, or corresponding amount of vehicle control. Medium
containing dead cells was pelleted with trypsinized cells, then re-suspended in 1X PBS
then counted with a hemocytometer after addition of trypan blue dye (Sigma-Aldrich) at
a 1:10 dilution.

Lipidomics analysis
Cells were collected by scrapping off from the dishes and washed twice with cold PBS.
Further preparation of samples and measurement of endogenous ceramides by LCMS/MS followed the protocol described previously

142

. Briefly, samples were

supplemented with internal standards, and 2 ml of isopropyl alcohol:water:ethyl acetate
(30:10:60; v:v:v) was added to the extracts. Samples were subjected to two rounds of
vortex and sonication followed by a 10-min centrifugation at 4000 rpm. The supernatant
or top layer was used as lipid extract and subjected to LC-MS/MS for analysis of
ceramide species. Lipid extraction and analyses were performed by the MUSC
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Lipidomics Shared Resources. Inorganic phosphates (Pi) were used for normalization.
Detailed protocol for inorganic phosphates analysis can be found in the Appendix.

Isolation of Ceramide-enriched membrane pores
We followed previously published protocol for isolating Giant Plasma membrane vesicles
143, 144

. In summary, cells were grown in 100 mm dishes to 80% confluency. These cells

were treated with Vehicle/ FTY720. The cells were rinsed twice with GPMV buffer (10
mM HEPES, 150 mM NaCl, 2 mM CaCl2, pH 7.4) and incubated with vesiculation buffer
(25 mM PFA/2 mM DTT in GPMV buffer, to prepare add 18µl of 4%wt/vol PFA
solution and 2µl of 1M DTT solution to 1mL GPMV buffer) for 1hr at 37ºC incubator.
GPMV (ceramidosomes) were collected and processed for electron microscopy.

Ceramide Docking to RIPK1
Using the software MOE from CCG

145

, a complete contiguous model of the kinase

domain from RIPK1 was created based on Xray-derived coordinates PDB:4NEU and
5HX6

146, 147

. The protein was protonated at T=310K, pH 7.3, salt at 200mM, and using

GB/VI electrostatics. The final structure was energy minimized using the AMBER12:
ETH forcefield. C16-ceramide was docked to the RIPK1 monomer using the entire
surface as a target. Initial placement calculated 100 poses using triangle matching with
London dG scoring, the top 50 poses were then refined using forcefield and Affinity dG
scoring, as we described previously 8, 141.
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Molecular interaction analysis
The heterodimer structures from pdb:3L82 and the best heterodimer output from ClusPro
for Fbxo4:Fxr1 were interrogated for intermolecular contacts. Protein contact thresholds
were 4.5 for hydrophobic interactions, 4.2 for ionic bonds, 2.5 for disulfide bonds with a
sequence separation of 4 and a network separation of 0. Molecular images were prepared
using MOE, as we described previously 8, 141.

Molecular modeling of ceramidosomes forming membrane pores
The theoretical model was created in several steps, as we have previously described.
First the top C16-RIPK1 results from the in-silico probe was duplicated in order to make
a symmetric RIPK1 homodimer containing two molecules of ceramide. Two mode
ceramides were added per molecule of RIPK1 and placed along the active site as a stack
in order to create homodimer of RIPK1 with six total ceramides. Finally, the CBD of
NMIIA was attached to each molecule of RIPK1. This was done using a prediction
derived from a CluPro protein-protein interaction simulation. Part of the recognition
domain of CBD from myosin molecules is defined and uses a conserved amphipathic
helix (E1547-K1555 in the case of NMIIA). A NMIIA (also known as MYH9) CBD domain
homology model was created using the CBD (also known as a globular tail domain
GTD)) from MyoVa (PDB:4KP3) 148. Using the structural file for RIPK1 and the CBD of
NMIIA, bimolecular docking was performed. Using the docking servers ClusPro server,
the RIPK1 structure (as described above) was uploaded as the ligand and the NMIIA
CBD structure was uploaded as the receptor. The binding residues were not selected nor
were any residues selected to block docking and default settings were used to allow
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maximum freedom of docking poses. The best pose and four of the top 10 poses indicated
an interaction with the E1547-K1555 helix and indicated it is favored interaction site. Using
protein superposition between the CluPro results and the aforementioned RIPK1 dimer,
the CBD was attached to each molecule of RIPK1.

Quantitative detection of ceramide-RIPK1 binding
H1341 cells were transfected with GFP-tagged RIPK1 WT, RIPK1 N169A, or empty
vector (pEGFP.N1). Cells were lysed by freeze-thawing in non-denaturing buffer: 50mM
Tris (pH7.4), 150 mM NaCl, 1mM EDTA, 0.5% NP-40 and 1:500 protease inhibitor
cocktail. Lysates (2 mg protein) were precleared with 40µl agarose beads. The precleared
lysates were incubated with GFP-magnetic beads at 4ºC for 18 hrs with gentle agitation.
The beads were then washed with 1X PBS and incubated with unlabeled ceramide or
biotin ceramide in 200µl of binding buffer. RIPK1-biotin-ceramide complexes were
quantified using competitive ELISA with streptavidin coated plates. The results were
analyzed using GraphPad Prism 7 software, as we previously described 8, 141.

Ultrastructural analysis using Transmission Electron Microscopy (TEM)
A549 cells were collected by scrapping off tissue culture plates. Rinsed with 1X PBS and
fixed in 2% glutaraldehyde in 1X PBS. After post-fixation with 2% (vol/vol) osmium
tetroxide, specimens were embedded in Epon 812, and sections were cut orthogonally to
the cell monolayer with a diamond knife. These sections were visualized with a
JEOL1010 transmission electron microscope.
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Immunogold analysis using transmission electron microscopy
H1341 cells were treated with FTY720/vehicle, collected by scraping the cells off the
plate using cell lifter. The cells were washed with 1X PBS and fixed for 15 minutes with
4% paraformaldehyde. The cells were washed again 2X with 1X PBS, and permeabilized
with 0.01% saponin. The saponin was rinsed off 2X with 1X PBS, followed by blocking
for 20 minutes with 1% BSA (in 1XPBS) and incubated with primary antibody (1:100) at
4ºC for 18 hrs. After primary antibody incubation, the cells were pelleted by centrifuging
for 5 minutes at 1,300 rpm. The pellets were then rinsed 2X with 1% BSA, before
incubation with secondary antibody (gold-conjugated Donkey anti-mouse/rabbit) at 1:200
dilution for 1 hr at room temperature. Finally, the cells were washed 2X with 1% BSA
and post-fixed with 1% glutaraldehyde (in 1XPBS) for 10 minutes, then kept in ddH2O.
The staining was enhanced by silver staining before imaging.

Scanning Electron Microscopy (SEM)
Post treatment, samples were fixed with primary fixative (2% glutaraldehyde, 2%
paraformaldehyde in 0.1 M cacodylate buffer pH 7.35). Secondary fixation was achieved
with 1% osmium tetroxide in 0.1 M cacodylate buffer. After both fixation steps, samples
were washed three times with ddH2O then dehydrated with increasing ethanol
concentrations (20% to 100%). Samples were submerged in 100% ethanol and critical
point drying was achieved with a Tousimis Autosamdri-931 (Rockville, MD). Before
imaging, 3-6 nm iridium was applied to samples and images were acquired with a
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Magellan 400 field emission scanning electron microscope (FEI) (Hillsboro, OR) at the
Notre Dame Integrated Imaging Facility.

Germline knockdown of zipper
Fly stocks were obtained from Bloomington Drosophila Stock Center and maintained at
25°C. zipper was knocked down in the germline by driving zipper shRNA using Gal4nos.NGT. Adult ovaries in F1 progeny from this cross were rudimentary.

Drosophila ovaries immunostaining and microscopy
Immunostaining of ovaries was performed as described earlier
at 1:100

150

149

. a-Ceramide was used

. a-1B1 was obtained from Developmental Studies Hybridoma Bank, Iowa

and used at 1:50 dilution. Confocal images were taken using Zeiss LSM 880 NLO
microscope and Plan-Apochromat 63x/1.40 Oil DIC objective. Images were analyzed
using Fiji (ImageJ).

Immuno-gold labeling of Drosophila ovaries
Isolated ovaries from D. melanogaster flies were stained with gold-labeled ceramide as
described in

151

. Briefly, paraformaldehyde tissues were sliced into ultra-thin sections

using a microtome. The sections were mounted on carbon-coated copper grids. The grids
were then rinsed, blocked and incubated with ceramide antibody, then gold labeled
antibody before contrast staining with uranyl acetate and imaging.
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FB1 exposure of D. melanogaster
10-15 adult male and female OregonR flies were exposed to food containing 100 µM
FB1. Flies not exposed to FB1 were used as control. F1 generation flies from exposed
and not exposed parents were used for immunostaining adult ovaries using a-1B1 and aCeramide.

Statistical analysis
Data were reported as mean ± standard deviation. Statistical analysis was performed by
ANOVA or Student’s t-test using Prism/GraphPad software version 7; p <0.05 were
considered statistically significant, as described previously 8, 141.
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CHAPTER THREE:

RESULTS
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1. FTY720 induces loss of PM integrity, which can be inhibited by Blebbistatin
To confirm that FTY720-mediated necroptosis was associated with plasma
membrane alteration, a known occurrence in necroptosis, we carried out live cell
imaging, transmission electron microscopy (TEM), and scanning electron microscopy
(SEM) studies. We treated GFP-expressing A549, non-small cell lung cancer cells with
FTY720 or vehicle (DMSO) and carried out live cell imaging over a period of 240
minutes. Our data showed that FTY720 induced membrane blebbing, followed by plasma
membrane rupture and necroptosis in a time dependent manner (Figure 7A-B). Using
A549 cells without GFP, we were also able to detect compromised plasma membrane
with YO-PRO1
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and propidium iodide (PI) dyes (Figure 7C), used to detect plasma

membrane breaks and cell death. We further detected the plasma membrane breaks
and/or holes using transmission electron microscopy and scanning electron microscopy in
cells treated with FTY720 (Figure 8 A-B).
Interestingly, FTY720-mediated blebbing and plasma membrane rupture was
largely abrogated when the cells were pretreated with blebbistatin

153

, a known inhibitor

of non-muscle myosin IIA (NMIIA)-mediated blebbing in A549 cells detected using live
cell imaging (Figure 9A-B) and trypan (Figure 9C). Concurrently, Blebbistatin
pretreatment inhibited the plasma membrane breaks/holes in cells, detected by SEM
(Figure 10). Thus, these data suggest that FTY720-mediated necroptosis is linked to
NMIIA-mediated blebbing, resulting in membrane rupture and cell death.
Moreover, alterations of the plasma membrane integrity and induction of
necroptotic cell death in response to FTY720 were also evident with YOPRO-1 and PI
dyes in H1341, a small cell lung cancer cell line, using live cell imaging (Figure 11A)
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and flow cytometry (Figure 11 B-C). This was confirmed using trypan blue exclusion
assay (Figure 11 D).
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Figure 7 : Loss of plasma membrane integrity in A549 cells in response to FTY720
A. A549-GFP cells were treated with 20µM FTY720 and their morphological changes
monitored over a period of 240 minutes. Frozen frames of the time lapse experiment
show plasma membrane blebbing before rupture and disintegration of cells treated with
FTY720, quantified in B. Data are means ± SD from three independent experiments,
analyzed by paired student t-test (n=3, *P= 0.002**P=0.004***P=0.002). C. Effect of
FTY720 on cells’ plasma membrane integrity. Live cell imaging in A549-GFP cells
shows plasma breakage as evidenced by incorporation of propidium iodide dye (red) in
A549 cells.

46

Figure 8 : Electron microphotographs A549 and H1341 cells after FTY720
treatment

A. TEM micrographs show plasma membrane breaks (compromised plasma membrane,
shown with black arrow) in FTY720 (20µM) treated A549 cells. B. SEM micrographs
show pores (shown with black arrows) and compromised plasma membrane in H1341
cells after FTY720 treatment (20µM), in a time-dependent manner.
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Figure 9 : Blebbistatin protects cells from FTY720-induced necroptosis
A. A549-GFP cells were pretreated with blebbistatin (12.5µM for 2hr) before FTY720
treatment shows and time lapse images were taken to monitor changes in morphology.
Blebbistatin treated cells showed protection from plasma membrane rupture induced by
FTY720, quantified in B, Data are means ± SD from three independent experiments,
analyzed by paired student t-test (n=3, *P=0.03**P<0.0008). C. Trypan blue in A549
cells pretreated with blebbistatin before FTY720 treatment.
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Figure 10 : Blebbistatin pretreatment inhibits FTY720-induced plasma membrane
holes
SEM micrographs show protection of the hole punctures in plasma membrane in cells
pretreated with blebbistatin (12.5 µM, 2 hr) before FTY720 treatment.
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Figure 11 : FTY720 treatment induces plasma membrane permeability and cell
death in H1341 cells
A. H1341 cells were imaged with YOPRO-1(green) and PI (red) dyes after exposure to
FTY720. B. Flow cytometry indicate increased necroptosis in cells treated with FTY720
versus vehicle (DMSO). Flow cytometry data is quantified in C. Data represents means ±
SD from three independent experiments, analyzed by paired student’s t-test (n=3,
*P=0.02). D. Trypan blue exclusion assay shows significant trypan blue inclusion with
FTY720 treatment. Data represents means ± SD from three independent experiments,
analyzed by paired student’s t-test (n=3, ***P<0.0001).
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2. FTY720 induces ceramide-enriched macrodomains on the PM
Because FTY720-induced necroptosis was independent of RIPK3 and MLKL

65

,

and FTY720 is known to modulate ceramide synthesis, we investigated whether FTY720mediated necroptosis is linked to ceramide generation, a bioactive lipid that is known to
alter membrane integrity and induce blebbing
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. Surprisingly, there were no detectable

changes in the overall abundance of ceramides in response to FTY720, measured by
LC/MS/MS in A549 total cell lysates (Figure 12).
In addition to the amounts of sphingolipids, their localization, also confers their
role in the cell 6-8, 155. Because of this, we investigated whether FTY720 exposure resulted
in the changes in ceramide subcellular localization. Interestingly, in A549 cells, FTY720
led to the formation of ceramide platforms/macrodomains on the plasma membrane, as
detected by immunofluorescence using two distinct anti-ceramide antibodies

150, 156

(Figure 13 A-B). There was no accumulation of S1P or cholesterol on the plasma
membrane, as detected by anti-S1P or anti-cholesterol antibodies respectively

157,158

(Figure 13 C-D). Moreover, treatment of cells with NBD-FTY720, a fluorescently
tagged FTY720, showed no sign of drug accumulation on plasma membrane of A549
cells (Figure 13 E), suggesting that FTY720 itself does not accumulate in ceramideenriched membrane macrodomains, which appear to be around 1-2 microns in diameter.
To confirm the presence of ceramide in the FTY720-mediated membrane
macrodomains, we depleted ceramides in H1341 cells by overexpressing acid ceramidase
(AC)

92, 159

, an enzyme that hydrolyzes ceramide to sphingosine and fatty acid. Ectopic

expression of AC using adenoviral particles (Ad-GFPAC), reduced total ceramide levels
(Figure 14 A) and abrogated the formation of ceramide-enriched membrane
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macrodomains (Figure 14 B-C). Figure 14 D Shows the expression levels of AC
compared to Ad-GFP control. Taken together, these data suggest that FTY720 exposure
induces the formation of membrane pores, which are enriched in endogenously generated
ceramides, altering plasma membrane integrity and inducing necrotic cell death.
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Figure 12 : FTY720 does not alter ceramide generation in A549 cells
A549 cells treated with FTY720 (20µM, 2hr) show no significant changes in the
ceramide levels in A549 cells after treatment. Data represents means ± SD from three
independent experiments, analyzed by paired student’s t-test (n=3, p=0.14).
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Figure 13 : FTY720 induces ceramide-enriched membrane macrodomains
A. A549 cells were treated for 2hr, with 20µM FTY720, stained for ceramide and F-actin
(Rhodamine phalloidin) and imaged using laser scanning confocal microscopy, evidence
of ceramide-enriched macrodomains in the plasma membrane. Right panel at the bottom
represents a zoom-out of the framed area. Scale bar represents 100 µm. B. A549 cells
treated with FTY720 (20µM, 2hr) stained with a different ceramide antibody (Rabbit
anti-ceramide) and F-actin also show the ceramide-enriched membrane macrodomains.
C. A549 cells treated with FTY720 (20µM, 2hr) and stained for S1P using anti S1P
antibody (1:100) and in D, cholesterol using anti-cholesterol antibody (1:100) as controls
for ceramide antibody staining. E. A549 cells treated with NBD-labeled FTY720 (20µM,
2hr) showed no fluorescence (FTY720) accumulation on the plasma membrane
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Figure 14 : FTY720-induced macrodomains are specifically made up of ceramide
A. Effects of AC overexpression on cells’ lipidomics profile was determined by LC/MS/MS,
there was significant decrease in total ceramide levels. Data represents means ± SD from three
independent experiments, analyzed by paired student t-test (n=3, *P=0.047). B. Ad-GFP-AC
was over-expressed in H1341 cells, the cells were treated with 20 µM FTY720 48 hr posttransduction and stained for ceramide-enriched membrane pores. This is quantified in C. Data
are means ± SD from three independent experiments, analyzed by paired student t-test (n=3
*P=0.02. **P=0.03). D. Western blot shows AC expression compared to Ad-GFP control.
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3. Ceramide-enriched macrodomains are novel structures
The ceramide-enriched macrodomains were not detectable in the Golgi, ER, early
endosomes, caveolin-enriched lipid microdomains, or exosomes in response to FTY720
in these cells (Figure 15 A). In addition, the macrodomains were only induced by
FTY720 and its non-phosphorylatable analogues. This was studied by exposing A549
cells to other sphingolipids, such as myriocin (as FTY720 is a myriocin analogue),
sphingosine, S1P and lysophosphatidic acid (LPA), all of which, did not induce the
ceramide-enriched macrodomains. Exposure of cells to FTY720 and its nonphosphorylatable analogue OSU-2S
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largely mediated ceramide-enriched membrane

pores formation (Figure 15 B). In addition, a FTY720-mimetic selected from the
ChemBridge library in silico (compound 5) was also able to induce ceramide-enriched
membrane pores, suggesting that ceramidosome formation is not dependent on selective
FTY720 exposure.
As expected, phosphorylated FTY720 (P-FTY720) did not induce ceramidosomes
(Figure 15 B). We confirmed this by knocking down sphingosine kinase 2 (SPHK2 or
SK2), the key enzyme that phosphorylates FTY720 to P-FTY720. Knocking down SK2
had no effect on ceramidosomes formation compared to controls, scrambled (SCR)shRNA-transfected and vehicle-treated cells (Figure 16 A-B). FTY720 and P-FTY720
levels were measured in A549 cells using mass spectrometry-based lipidomics

142

(Figure 16 C) and data showed significant decrease in P-FTY720 with SK2 knockdown,
further confirming that ceramidosomes were induced by FTY720 but not P-FTY720.
Figure 16 D. shows the mRNA expression levels of SK2 after knockdown with shRNA.
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Figure 15 : Ceramide enriched-macrodomains are novel structures and are
induced by FTY720 and its non-phosphorylatable analogues
A. A549 cells were treated with FTY720 and stained for ceramide and different organelle
markers GM130 (golgi) calnexin (ER), Eea1(Early endosomal markers), caveolin-1
(caveolin-1-enriched lipid rafts), CD63 (Exosomes). Ceramide-enriched membrane pores
did not co-localize with any of the stained organelles. B. A549 cells were treated with
different lipid compounds (20 µM), ceramide and F-actin (Rhodamine phalloidin) were
labeled to check evidence of ceramide-enriched membrane pores with
immunofluorescence.
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Figure 16 : SK2 knockdown does not affect FTY720-induced ceramide-enriched
macrodomains
A. H1341 cells with stable SK2 knockdown were stained for ceramide-enriched
membrane pores. The ceramide-enriched macrodomains are quantified in B, using
ImageJ. Data represents means ± SD from three independent experiments, analyzed by
paired student t-test (n=3, ns= not significant *P=0.05, **P=0.04). C. Lipidomics
analysis of the level of FTY720 and P-FTY720 in H1341 cells with SK2 stable
knockdown. Data represents means ± SD from three independent experiments, analyzed
by paired student t-test (n=3, **P<0.0001) D. qRT-PCR data shows the level of SK2
mRNA after knockdown. Data represents means ± SEM from three independent
experiments, analyzed by paired student t-test (n=3, **P<0.0001).
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4. Different cell lines respond differently to FTY720 to form Ceramide-enriched
membrane pores
During our experiments, we found that H1341 cells required almost tenfold less
FTY720 to induce ceramide-enriched pores compared to A549. In H1341 cells, induction
of ceramidosomes was detected with 0.1-1 µM FTY720 for 60 min as opposed to 10µM
in A549 cells (Figure 17 A-C), showing cell specificity and unique response to FTY720.
Interestingly, while ceramide-enriched membrane pores formation in response to FTY720
was evident in multiple cancer lines including H1650 (non-small cell lung cancer,
NSCLC), H1341 (small cell lung cancer, SCLC) and 22A (head and neck squamous cell
carcinoma, HNSCC) (Figure 18 A), they were not detected in non-cancerous skin
keratinocytes, normal human lung fibroblasts (NHLF) and NIH3T3 mouse embryonic
fibroblasts (Figure 18 B). Collectively, these data suggest that FTY720 and FTY720
mimetics, but not P-FTY720, mediate the formation of ceramidosomes in various cancer
cells, but not in non-cancerous keratinocytes or fibroblasts, in a dose and time-dependent
manner preceding blebbing, lysis of the plasma membrane and necroptosis. The
mechanisms mediating these differences between cell lines remain to be investigated.
Given the novelty and specificity of these ceramide-enriched membrane pores formed by
FTY720, we herein coin the name “ceramidosomes” for them.
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Figure 17 : FTY720 dose titration shows different sensitivity between H1341 and
A549 lung cancer cells
A. H1341 and A549 cells were treated with increasing concentrations of FTY720 for two
hours and stained with anti-ceramide antibody and Rhodamine phalloidin to check
evidence of ceramide-enriched membrane pores with immunofluorescence. B. A time
course experiment was carried out in H1341 cells. The cells were treated with 10 nM
FTY720 for different time periods and stained with anti-ceramide antibody and
rhodamine phalloidin to check evidence of ceramide-enriched membrane pores with
immunofluorescence. The ceramide-enriched membrane pores are quantified in C. Data
represent means ± SD from three independent experiments, analyzed by paired student ttest (n=3 *P=0.01).
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Figure 18 : Cancer cells but not non-cancerous cell form ceramide-enriched
membrane macrodomains
A. Multiple cancer cell line were treated with Vehicle (DMSO) or 20 µM FTY720 for 2
hr and stained for ceramide and F-actin. B. Non-cancerous cells (keratinocytes, normal
human lung fibroblast (NHLF) and NIH3T3) were treated with FTY720 (20µM for 2hr)
or vehicle and showed no evidence of ceramide-enriched membrane pores.
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5. Ceramide in FTY720-induced ceramidosomes is mainly C16-ceramide
To investigate the source of the ceramide enrichment in membrane pores in
response to FTY720, we generated A549 cells stably expressing shRNAs against
enzymes that catalyze ceramide generation. We knocked down neutral sphingomyelinase,
SMase (nSM1-3), serine pamitoyl transferases, SPT (SPT1-3), and Ceramide synthases,
CerS1, CerS2, CerS4, CerS5, and CerS6 using lentiviral particles. We omitted CerS3
because of its selective expression in skin and testes

161

. ShRNA-dependent knockdown

of nSMases (Figure 19 A) or SPT enzymes (Figure 19 B-D) had no effect on
ceramidosomes formation with/without FTY720.
Interestingly, knockdown of ceramide synthase 5 or 6, which generate C16ceramide, but not CerS1, CerS2, or CerS4, abrogated ceramidosomes and protected cells
from necroptosis in response to FTY720 (Figure 20 A-B), (mRNA levels are shown in
Figure 20 C). Reduction of C16-ceramide by silencing CerS5 and/or CerS6 was
confirmed by lipidomics compared to Scr-shRNA-transfected controls (Figure 20 D).
Thus, these data suggest that ceramidosomes mainly contain C16-ceramide generated by
CerS5 and/or CerS6 in response to FTY720. The fact that the SPT enzymes did not affect
ceramidosomes formation suggests a possible role for the salvage pathway in generating
the C16 ceramide generation for ceramidosomes formation.
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Figure 19 : Sphingomyelinases and serine pamitoyl transferases are not involved in
ceramidosomes formation

A. The effects of genetic loss of SMases were studied in A549 cells with stable
knockdown of different nSMases. Knocking down nSMases did not abrogate ceramideenriched membrane pores. B. H1341 cells with stable SPT knockdown were stained for
ceramide-enriched membrane pores. Knocking down SPT did not significantly abrogate
ceramide-enriched macrodomains. This is quantified in C. Data represents means ± SD
from three independent experiments, analyzed by paired student t-test (n=3, *P=0.01). D.
mRNA expression levels in the shSPT stable knockdown cells were determined by qRTPCR. Data represents mean ± SEM from three independent experiments, analyzed by
paired student t-test (n=3, *P=0.046).
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Figure 20 : C16 ceramide in ceramidosomes is generated by CerS5 and CerS6
A. Effects of genetic loss of ceramide synthases on ceramidosomes formation were
measured using immunofluorescence with ceramide antibody and Rhodamine phalloidin
(F-actin) in H1341 cells with CerS1 CerS2, CerS4, CerS5, CerS6 shRNA, compared to
scramble (shscr) shRNA. ceramide-enriched membrane pores were manually quantified
B. Data represent means ± SD from three independent experiments. Analyzed by student
t-test (n=3, *P<0.05) Scale bar represents 100 µm. C. mRNA expression levels in the
shCerS 1, 2, 4, 5, 6 stable knock-down cells were determined by qRT-PCR. Data
represents mean ± SEM from three independent experiments, analyzed by paired student
t-test (n=3, *P=0.04, **P=0.005, ***P=0.001, ****P<0.0001). D. Lipidomics analysis
was carried out in H1341 cells with stable CerS5 and 6 knock-down. Data are means ±
SD from three independent experiments, analyzed by paired student t-test (n=3).
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6. Ceramidosomes mediate RIPK1-dependent necroptosis
Because our previous studies indicated FTY720-mediated necroptosis was
dependent on RIPK1, but not RIPK3 65, we assessed whether RIPK1 played any role in
the formation of ceramidosomes in response to FTY720. To determine if RIPK1 is
localized within ceramide-enriched membrane pores, we first measured the colocalization of RIPK1 and ceramide by immunofluorescence using anti-RIPK1 and anticeramide antibodies. FTY720 exposure induced the co-localization of RIPK1 and
ceramide compared to vehicle-treated controls within plasma membrane (Figure 21 A).
This co-localization between RIPK1 and ceramide was also detectable by immunogold
TEM using gold labeled anti-RIPK1 (labeled with 10 nm gold particles) and anticeramide (labeled with 1.4 nm gold particles) antibodies (Figure 21 B) and proximity
ligation assay (PLA) using anti RIPK1 and anti-ceramide antibodies (Figure 21 C-D) in
response to FTY720 compared to vehicle-treated controls. Thus, these data suggest that
RIPK1 is co-localized with ceramide at the plasma membrane within ceramidosomes in
response to FTY720-mediated stress.
Then, to determine if RIPK1 was necessary for ceramidosome formation, we
measured the effects of RIPK1 knockdown on ceramidosomes in response to FTY720.
ShRNA-mediated knockdown of RIPK1 prevented ceramidosomes formation in response
to FTY720 (Figure 22 A-B), (protein expression in panel C), and protected cells from
necroptosis compared to Scr-shRNA-transfected and vehicle-treated cells (Figure 22 D).
In contrast, knocking down RIPK3 using shRNA had no effect on ceramidosome
formation (Figure 23 A-B) or cell death (Figure 23 C). (mRNA levels are shown in
65

Figure 23 D). Given that RIPK3 is known to activate MLKL, which induces membrane
pores for the execution of necroptosis

61, 162

, we also measured the effects of MLKL

inhibition on ceramide-enriched membrane pores formation, using a pharmacological
inhibitor necrosulfonamide (NSA)

162

. NSA-mediated MLKL inhibition had no effect on

FTY720-mediated ceramidosome formation (Figure 23 E-F) or necroptosis as tested by
trypan blue assay (Figure 23 G).
As an additional control, we also explored other known pore-forming proteins that
could be involved in the execution of FTY720-mediated necroptosis. To achieve this, we
investigated the effects of purinergic receptor protein (P2X7), which is known to form
membrane pores in response to cytotoxic stress such as increased ATP accumulation 163.
Our data showed that pharmacological inhibition of P2X7 using inhibitor AZ10606120
164

had no effect on induction of ceramidosomes (Figure 24 A-B) or necroptosis, (Figure

24 C) in the presence of FTY720. Thus, these data are consistent with our previous
findings, indicating that while RIPK3 and MLKL were dispensable, RIPK1 is necessary
for FTY720-induced ceramidosome formation and necroptosis.
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Figure 21 : RIPK1 colocalizes with ceramide in FTY720-induced ceramidosomes
A. Colocalization of RIPK1 and ceramide was measured by confocal microscopy. A549
cells were treated with 20 µM FTY720 for 2 hr and stained with anti-ceramide antibody
and anti- RIPK1 antibody and detected by immunofluorescence. Colocalization of RIPK1
and ceramide is evident on the plasma membrane in response to FTY720 treatment. B.
RIPK1-ceramide colocalization was further detected by immuno-gold TEM. H1341 cells
were treated with FTY720 or Vehicle (DMSO). The electron microphotograph shows
increased RIPK1 (10 nm gold) association with ceramide (1.4 nm gold) in cells treated
with FTY720. C. This was confirmed in A549 cells by proximity ligation assay (PLA).
Cells treated with FTY720 (20 µM) had increased RIPK1-ceramide association. This is
quantified in D. Data represent means ± SD from five independent experiments, analyzed
by paired student t-test (n=5 **P=0.006).
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Figure 22 : Knocking down RIPK1 inhibits ceramidosomes formation

A. To study effects of RIPK1 silencing on ceramidosomes formation, A549 cell were
stably transfected with lentiviral shRNA against RIPK1. These cells were treated with 20
µM FTY720 or vehicle for 2 hr and stained with anti-ceramide antibody and Rhodamine
phalloidin (F-actin). shRIPK1 cells had significantly less ceramidosomes formed as
quantified in B. Data represent means ± SD from three independent experiments,
analyzed by paired student t-test (n=3 *P=0.01). C. Western blot shows the RIPK1
expression after knockdown in with RIPK1 shRNA lentiviral particles in A549 cells.
RIPK1 was knocked down over 70%. D. LDH assay was used to study effect of RIPK1
knockdown on FTY720-induced necroptosis. shRIPK1-A549 cells were less sensitive to
FTY720 treatment compared to shscr cells. Data represent means ± SD from three
independent experiments, analyzed by paired student t-test (n=3 *P=0.048, **P=0.008,
ns=not significant).
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Figure 23 : RIPK3 and MLKL are dispensable in FTY720 induced ceramidosomes
formation and necroptosis
A. H1341 cells with stable RIPK3 knockdown were investigated for presence of
ceramidosomes with/without FTY720 treatment (10µM 1hr). These were quantified as
shown in B, Data are means ± SD from three independent experiments, analyzed by
paired student t-test (n=3, *P=0.002). C. LDH Assay in shRIPK3 cells treated with
FTY720 (20µM, 3hr or vehicle control). Data represents means ± SD from three
independent experiments, analyzed by paired student t-test (n=3, *P=0.02, **P=0.005).
D. mRNA expression of RIPK3 in the RIPK3 stable knockdown cells was determined by
qRT-PCR. Data represents means ± SEM from three independent experiments, analyzed
by paired student t-test (n=3, *P=0.046). E. H1341 cells were pretreated with NSA
(MLKL inhibitor, 2.5µM for 2hr). The ceramide-enriched pores are quantified in F. Data
represents means ± SD from three independent experiments, analyzed by paired student ttest (n=3, *P=0.04). G. Trypan blue assay was carried out in the NSA pretreated H1341
cells. Data represents means ± SD from three independent experiments, analyzed by
paired student t-test (n=3, *P=0.01).
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Figure 24 : P2X7 is not involved in FTY720 induced ceramidosomes or necroptosis
A. H1341 cells were pretreated with AZ10606120 (P2X7 inhibitor, 5µM, for 1hr) before
treatment with FTY720. The cells were then stained for the ceramidosomes. This is
quantified in B. Data represents means ± SD from three independent experiments,
analyzed by paired student t-test (n=3, *P=0.04). C. Trypan blue assay was carried out in
the AZ10606120 pretreated cells. Data represents means ± SD from three independent
experiments, analyzed by paired student t-test (n=3, *P=0.01).
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7. RIPK1 directly binds ceramide to form ceramidosomes
Ceramide-protein interaction is important for various crucial biological roles. For
instance, ceramide binding to LC3BII targets autophagolysosomes to the mitochondria to
induce lethal mitophagy

7, 8

. Additionally, ceramide has been shown to bind CERT

(ceramide transport protein) for trafficking to the golgi for synthesis of sphingomyelin
165

. To investigate if the association between ceramide and RIPK1 was due to their

binding, we first measured ceramides by lipidomics after immunoprecipitation of RIPK1
using anti-RIPK1 antibody, and lipid extractions on agarose beads used for pulling down
possible RIPK1-ceramide complexes, as we described previously

8, 141

(Figure 25 A-B).

These data revealed that there was an increase only in C16-ceramide in FTY720 treated
cell extracts bound to RIPK1 compared to controls (vehicle-treated). Of note, FTY720
did not affect RIPK1 expression levels (Figure 25 C). In reciprocal studies, binding of
ceramide with RIPK1 was measured in-vitro using biotinylated C6-ceramide and
recombinant human RIPK1, which were isolated by avidin-conjugated agarose beads.
The amount of RIPK1 bound to biotin-ceramide was measured by ELISA using antiRIPK1 antibody. It was found that C6-ceramide bound to RIPK1 with a Kd of 1.9 nM
(Figure 25 D), and the stoichiometry of RIPK1-ceramide binding was found as 1:2.4,
calculated as we described previously

141

. These findings further confirmed ceramide-

RIPK1 binding and indicate that at least in-vitro, RIPK1- ceramide binding is
independent of the fatty acid chain length of ceramide. In addition, formation of dimers
of RIPK1 upon FTY720 exposure was detected using non-denaturing western blot
analysis (Figure. 25 E). These biochemical data were then used for in silico modeling of
RIPK1-ceramide complex, containing RIPK1 dimer associated with four molecules of
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C16-ceramide (Figure. 25 F). Molecular docking and simulations were done using the
already existing X-ray crystal structure of RIPK1

166

(PDB: 4NEU and 5HX6). The top

ranked model of the RIPK1-ceramide complex identified potential residues of RIPK1 that
were important for ceramide binding, including D147, N148 and N169 residues.
To confirm and validate the model for RIPK1-ceramide binding, we performed
site directed mutagenesis to generate D147A, N148A and N169A conversions and
measured their effects on co-localization with ceramide at the plasma membrane and
necroptosis. The WT-RIPK1-GFP was co-localized with ceramide at the plasma
membrane, whereas the association between ceramide and D147A-RIPK1-GFP or
N169A-RIPK1 at the plasma membrane was reduced compared to WT-RIPK1 in
response to FTY720 (Figure 26 A-B). Interestingly, N186A mutants, which was
identified as a weak ceramide interacting residue, co-localized largely with ceramide in
response to FTY720 (Figure 26 A-B). Live cell imaging of these mutants with PI dye
after FTY720 treatment further showed the protective effect of the N169A mutant
(Figure 27 A-B). The loss of ceramide binding of the N169A-RIPK1 was confirmed
using biotin-C6-ceramide and partially purified N169A-RIPK1-GFP, as described above,
which showed no binding (Figure 28 A-B). Thus, these data suggest that RIPK1ceramide binding plays a key role for the generation of ceramidosomes and induction of
necroptosis after FTY720-mediated cellular stress.
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Figure 25 : RIPK1 binds Ceramide in response to FTY720
A. Lipidomics analysis of agarose beads after RIPK1 pull down show significant binding
of endogenous C16-ceramide to RIPK1. Data are means ± SD from three independent
experiments, analyzed by paired student t-test (n=3, p =0.04) in response to FTY720. B.
Western blot showing RIPK1 after pull down with anti-RIPK1 antibody and agarose
beads in DMSO (vehicle) versus treated (FTY720) cells. C. Western blot analysis of
H1341 cells treated with FTY720 shows no change RIPK1 relative protein abundance
compared to vehicle treated cells. D. In-vitro ceramide binding assay with purified
recombinant human RIPK1 show binding to biotinylated C6-ceramide with a Kd of
~1.908 nM. E. Western blot with anti-RIPK1 antibody shows the formation of RIPK1
dimers in non-reducing conditions in cells treated with FTY720 compared to vehicletreated cells. F. Molecular model of RIPK1 and ceramide showed RIPK1 dimers with 4
ceramide molecules. Molecular images were prepared using MOE.
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Figure 26 : RIPK1-ceramide binding is crucial for ceramidosomes formation and
necroptosis
A. Confocal images showing ceramide-enriched membrane pores formation with the
RIPK1 mutants over-expressed in shRIPK1 cells. B. quantification of ceramidosomes in
A. Data represents means ± SD from three independent experiments, analyzed by paired
student t-test (n=3 *P<0.05).
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Figure 27 : N169A RIPK1 mutant protects cells from FTY720-induced cell
death
A. To determine effect of the RIPK1 mutants on cell death, live cell imaging experiment
was carried out on shRIPK1 cells with EV, WT RIPK1 or N169A RIPK1 overexpression. Cells with mutant RIPK1 showed a delay in PI dye inclusion, quantified in B.
Data represents means ± SD from three independent experiments, analyzed by paired
student t-test (n=3 *P=0.05, **P=0.02).
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Figure 28 : In-vitro RIPK1 mutants-ceramide binding assay
A. In-vitro binding assay of partially purified empty vector (EV), WT or N169A RIPK1
using biotinylated C6 ceramide. Data represents means from three independent
experiments. B. Western blot analysis shows the expression of WT and N169A RIPK1
after pull down for use in the in-vitro ceramide binding assay with biotinylated-C6ceramide.
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8. The ceramide-RIPK1 complex is trafficked to PM through vesicular trafficking
Transport of “cargo”, including lipids and lipid complexes intracellularly from
their site of synthesis to target sites can occur in vesicular and non-vesicular fashion

167

.

Vesicular trafficking is known to be dependent on temperature, with low temperatures
inhibiting vesicular trafficking

168

. This factor can be used to distinguish between

vesicular and non-vesicular trafficking.
To determine whether ceramide-RIPK1 complexes are translocated to the plasma
membrane via vesicular or non-vesicular trafficking, we treated A549 cells with FTY720
at 37°C or at 4°C, and measured ceramide-RIPK1-enriched membrane pores. The data
demonstrated that while ceramidosomes were formed in cells incubated at 37oC in
response to FTY720, incubation of cells at 4oC largely prevented the formation of
ceramidosomes at the plasma membrane. Interestingly, when cells that were incubated
initially at 4oC were later transferred to 37oC, formation of ceramidosomes was restored
(Figure 29 A-B), indicating the involvement of temperature sensitive trafficking, which
is usually indicative of vesicular transport. This was confirmed by pretreating A549 cells
with a known vesicular trafficking inhibitor, Brefeldin A (10 µg/mL) 169 for 24 hr before
FTY720 exposure, which prevented ceramide-RIPK1 complex transport to the plasma
membrane (Figure 29 C-D).
We found non-muscle myosin IIA (NMIIA) was critical for the ceramidosomes
trafficking because blebbistatin pretreatment attenuated the formation of ceramidosomes
(Figure 29 E). However, pharmacologic inhibitors of kinesin spindle protein (ARRY520)
170

, kinesin (K858)

171

and Dynein (ciliobrevin)

172

, had no effect on the formation of

ceramide-RIPK1-enriched pores after FTY720-mediated stress (Figure 29 E).
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Interestingly, the vesicular trafficking of the ceramide-RIPK1 complex was also
dependent on an intact actin cytoskeleton, because inhibiting actin polymerization using
Latruculin A (Lat A)

173

attenuated ceramidosome formation (Figure 29 F-G). Thus,

these data suggest that NMIIA is key for the transport of ceramide-RIPK1 complex to the
plasma

membrane,

and

that

the

ceramide-RIPK1-NMIIA

complex

integrates

ceramidosomes to form a membrane macrodomain and subsequent membrane pores
leading to FTY720-induced necroptosis.
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Figure 29 : Ceramidosomes are trafficked to the plasma membrane via vesicular
trafficking
A. Shows cells treated with Vehicle/ FTY720 and incubated at 4º C or 37º C for two
hours or 4º C followed by 37º C. This is quantified in panel B, Data are means ± SD
from three independent experiments, analyzed by paired student t-test (n=3, ns=not
significant *P =0.007, **P=0.005). C. A549 cells were pretreated with Brefeldin A
(10µg/µl for 24hr) before FTY720 treatment. The cells were then stained for ceramide
and F-actin as shown. This is quantified in panel D. Data are means ± SD from three
independent experiments, analyzed by paired student t-test (n=3, *P =0.04, **P=0.03). E.
Pharmacological inhibitors against Kinesin or dynein or NMIIA were used to pretreat
A549 cells before treatment with FTY720 and immunofluorescence staining for
ceramide-enriched pores. F. A549 cells were pretreated with latrunculin A and treated
with FTY720 for 1 hr. Ceramide- enriched pores are quantified in G. Data represent
means ± SD from three independent experiments, analyzed by paired student t-test (n=3,
**P=0.002).
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9. NMIIA traffics RIPK1-ceramide complex to the plasma membrane
Non-muscle myosin IIA, NMIIA, coded by the MYH9 gene is known to bind and
traffic Golgi glycosyltransferase to the ER

174

. Not only has NMIIA been implicated in

intracellular vesicle trafficking 175, 176 but also, it has been shown to be important in tissue
folding in D. melanogaster

177

, suggesting a conserved role of this protein in both

mammalian and lower organism level. Interestingly, MYH9 knock out is embryonic
lethal in mice 178 and D. melanogaster 179, 180 .
Based on the observation that blebbistatin, an inhibitor of NMIIA, also protected
ceramide-enriched pores, we then hypothesized that NMIIA, recently identified as a
tumor suppressor protein

181, 182

, might be key for the trafficking of the ceramide-RIPK1

complex to the plasma membrane to form ceramidosomes in response to FTY720. To test
this hypothesis, we first measured the co-localization of NMIIA with ceramide and
RIPK1 using immunofluorescence. FTY720 exposure induced the co-localization of
NMIIA with ceramide and RIPK1 (Figure 30 A-B) compared to vehicle-treated controls.
This was confirmed with tri-color colocalization of ceramide-RIPK1 and NMIIA (Figure
30 C). The co-localization of NMIIA and RIPK1 within ceramidosomes at the plasma
membrane in response to FTY720 was also consistent in TEM studies performed using
gold labeled anti-NMIIA (labeled with 1.4 nm gold particles) and anti-RIPK1 (labeled
with 10 nm gold particles) (Figure 30 D).
Interestingly, PLA analysis showed that while NMIIA associated highly with
RIPK1 (Figure 31 A-B), there was almost no detectable interaction between NMIIA and
ceramide (Figure 31 C-D). Thus, these data suggest that FTY720-mediated
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ceramidosomes are transported to the plasma membrane by NMIIA via RIPK1-NMIIA
association.
Next, we determined whether NMIIA knockdown inhibited the formation of
ceramidosomes in response to FTY720. NMIIA knockdown reduced the formation of
ceramidosomes (80%) in response to FTY720 compared to shscr-transfected and vehicletreated controls (Figure 32 A-B). Down-regulation of NMIIA using shRNA also
protected A549 cells from FTY720-mediated necroptosis compared to controls (Figure
32 C). The expression levels of NMIIA after knockdown are shown in Figure 32 D.
Using the tricolor Zstack confocal image, we generated a three-dimensional (3D)
image of the ceramide-RIPK1-NMIIA complex at the plasma membrane using the using
ImarisCell software (Figure 33).
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Figure 30 : NMIIA colocalizes with ceramide and RIPK1 on the plasma membrane
in response to FTY720
A. Colocalization of NMIIA with ceramide in ceramide-enriched membrane pores was
detected by immunofluorescence using anti-ceramide and anti-NMIIA antibodies (Insert
on bottom right shows a zoom-out of the framed area). B Colocalization of RIPK1 and
NMIIA in ceramide-enriched membrane pores was detected by immunofluorescence
using anti-ceramide and anti-RIPK1 antibodies. C. Tricolor immuno-fluorescence of
A549 cells with NMIIA, RIPK1, and ceramide antibodies shows the colocalization of the
three at the plasma membrane in response to FTY720. D. Immuno-gold TEM show
colocalization of NMIIA (1.4 nm) and RIPK1 (10 nm) in H1341 cells treated with
FTY720.
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Figure 31 : NMIIA interacts with RIPK1 in the RIPK1-ceramide-NMIIA complex
A. PLA assay in A549 cells detects RIPK1 and NMIIA increased association in response
to FTY720. PLA assay is quantified in B. Data represent means ± SD from three
independent experiments, analyzed by paired student t-test (n=5 **P=0.004). C. PLA
assay did not show interaction between ceramide-NMIIA interaction in response to
FTY720. The detected PLA signal is quantified in D. Data represent means ± SD from
three independent experiments, analyzed by paired student t-test (n=5 ns=not significant).
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Figure 32 : NMIIA inhibits ceramidosomes formation and protects cells from
cell death
A. A549 cells with stable NMIIA knockdown (shMYH9) were stained for ceramideenriched membrane pores using anti-ceramide and anti-RIPK1 antibodies. This is
quantified in B. Data represent means ± SD from three independent experiments,
analyzed by paired student t-test (n=3 *P=0.01, **P=0.003). C. LDH assay in stable
shMYH9 cells treated with increasing doses of FTY720 show significant protection from
FTY720 induced cell death. Data represent means ± SD from three independent
experiments, analyzed by paired student t-test (n=3 *P=0.004, **P=0.01, ***P£0.0008).
D. Western blot of A549 cells with stable knockdown of NMIIA.
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Figure 33 : 3D model of ceramidosome
ImarisCell model (derived from a Zstack confocal image) shows the spatial interaction of
components of ceramidosomes
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10. NMIIA interacts with RIPK1 for the trafficking of the RIPK1-ceramide complex
to the PM
Because our studies suggest that trafficking of ceramide-RIPK1 complex to the
plasma membrane was facilitated by NMIIA via its interaction with RIPK1, we then
generated a model of the NMIIA-RIPK1 interaction, containing the RIPK1-ceramide
complex using molecular modeling and simulations (Figure 34 A-B). This model (the
top ranked model among various others) suggested a few possible residues of RIPK1 that
might be involved in NMIIA interaction, including L112, C256, R258, L293, and E295
(Figure. 34 B). We then confirmed this model by measuring the effects of WT-RIPK1GFP compared to various mutants of RIPK1 with L112A, C256A, R258A, L293A, or
E295A conversions with the GFP tag on NMIIA interaction using immunofluorescence
(Figure 35 A-B). Western blotting (Figure 35 C) shows the expression of the mutants
after overexpression. The data showed that alterations of RIPK1-NMIIA interaction due
to R258, L293A or E295A mutations on RIPK1 limited the formation of ceramidosomes
in response to FTY720. We picked L293A mutant for live cell imaging using YOPRO-1
and PI and the mutation also protected cells from FTY720-mediated necroptosis
compared to the cells expressing WT-RIPK1-GFP (Figure 36 A-B).
To visualize the ceramide-RIPK1-NMIIA complex (ceramidosome) that forms
large pores on the plasma membrane in response to FTY720, we isolated ceramidosomes
from the plasma membrane by using the method for the isolation of giant plasma
membrane vesicles (GPMV)

183

. This method induces the vesiculation of the plasma

membrane (“pinching off” of plasma membrane), including FTY720-induced
ceramidosomes, which we can further study using different applications. Figure 37 A
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shows an image of how the GPMV appear, when induced in A549-GFP cells. We treated
H1341 cells with 10µM FTY720/vehicle and isolated the GPMV from both conditions.
After isolation, the GPMVs were fixed and labeled using gold-labeled anti-ceramide,
anti-RIPK1 or anti-NMIIA antibodies for visualization by TEM (Figure 37 B). The TEM
images of these GPMVs demonstrate that while ceramide surrounds the inner channel,
RIPK1 and NMIIA appear to have a general distribution within these vesicles consistent
with the molecular modeling (Figure 34 A) and the three-dimensional image (Figure
33).

Overall,

these

data

suggest

that

RIPK1-NMIIA

interaction,

involving

R258/L293/E295 residues of RIPK1, plays a key role for the transport of ceramideRIPK1 complex to the plasma membrane for the formation of ceramidosomes and large
membrane pores, involved in the execution of FTY720-mediated necroptosis.
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Figure 34 : Ceramidosome model showing key residues for interaction
A. Predicted model of ceramidosomes, showing ceramide, RIPK1, and NMIIA, (brown,
green and blue respectively). The right panel (B) highlights the residues predicted to be
key for RIPK1 and ceramide, as well as RIPK1-NMIIA binding.
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Figure 35 : R258, L293 and E295 residues in RIPK1 are important for RIPK1NMIIA binding
A. RIPK1 mutants were overexpressed in shRIPK1 cells, the cells were then stained for
ceramidosomes. These are quantified in B. Data represent means ± SD from three
independent experiments, analyzed by paired student t-test (n=3 *P=0.05, **P=0.005). C.
Western blot showing the expression of the RIPK1 mutants in H1341 cells.
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Figure 36 : L293A mutant protects cells from FTY720-induced cell death
A. To determine effect of the RIPK1 mutants on cell death, RIPK1 mutant L293A, was
overexpressed in shRIPK1 H1341 cells. The cells were then treated with 20µM FTY720
and monitored over time for inclusion of propidium iodide dye with confocal live cell
imaging. This is quantified in B. Data represents means ± SD from three independent
experiments, analyzed by paired student t-test (n=3 *P=0.02, **P=0.004).
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Figure 37 : Isolated ceramidosomes show ceramide, RIPK1 and NMIIA staining
A. Image shows induced plasma membrane “pinching off” (GPMV) in A549-GFP cells.
Ceramidosomes were isolated through this method. B. Isolated ceramidosomes were
stained for ceramide, RIPK1, NMIIA staining, in immunogold TEM. scale bar represents
200 nm.
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CHAPTER FOUR: DISCUSSION AND FUTURE DIRECTIONS
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DISCUSSION
In this study, our data demonstrate that the ceramide-RIPK1-NMIIA complex
forms large membrane pores at the plasma membrane, which are referred to here as
ceramidosomes. The formation of ceramidosomes in response to FTY720-mediated stress
resulted in plasma membrane blebbing, leading to compromised membrane integrity and
necroptosis in cancer cells. FTY720/ceramidosome-mediated necroptosis was RIPK1dependent, however, unlike canonical necroptosis, RIPK3 and MLKL were dispensable
in this process. We suggest that in place of MLKL, ceramidosomes are serving as the
“executioner” in FTY720-mediated necroptosis, a term used to describe MLKL in
canonical necroptosis, for its pore forming function 184, 185, 186.

Figure 38 : Graphical abstract

PP2A activation by FTY720/OSU-2S leads to the dimerization of RIPK1 and binding to
C16 ceramide. This complex is then trafficked to the plasma membrane by NMIIA,
where it forms pores on the plasma membrane and result in cell death. In nonpathological setting, the ceramidosome complex could be serving more of regulatory
channel role than a pore signaling for cell death.
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It has been known that ceramide induced necroptosis in response to TNF-alphamediated stress in L929 cells, which is protected by hydrolysis of ceramide by acid
ceramidase

187

. Studies by Lang et. al., also suggested that ceramide-mediated

necroptosis played a key role in hyperosmotic-induced cell death in erythrocytes (suicidal
death of erythrocytes, eryptosis), which was associated with membrane blebbing and
necrosis

188

. However, the mechanisms by which ceramide induces membrane blebbing

and necroptosis have been unknown. A recent study showed that ceramide
nanoliposomes induced MLKL-dependent necroptosis in ovarian cancer cells

189

. Our

data suggest that FTY720-mediated necroptosis is dependent on the formation of novel
ceramide-enriched membrane pores (ceramidosomes), which are made up of ceramideRIPK1/NMIIA complex. Ceramidosome-mediated necroptosis appears to be distinct
from canonical necroptosis, as RIPK3 and MLKL were dispensable for this process in
response to FTY720-induced stress.
Although ceramide was modeled to form lipid channels in vitro, and these
ceramide channels were reported to exist at the mitochondrial membrane, which are
disassembled by anti-apoptotic Bcl-2 family proteins

190, 191

, whether ceramide channels

in mitochondria play any roles in the regulation of cell death remain unknown. To this
end, our studies demonstrate that FTY720-mediated ceramidosomes are formed
intracellularly with the involvement of ceramide-RIPK1 association and are then
trafficked to the plasma membrane through actin filaments by NMIIA. It has been shown
that NMIIA is involved in the trafficking of protein cargo to various biological
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membranes with distinct functions such as controlling exocytosis or positioning of
organelles in cells
function of NMIIA

192, 193

. Our data are also consistent with the tumor suppression

194

, as its genetic deletion resulted in squamous cell carcinoma

development in mice through inactivation of p53 signaling, similar to the prevention of
ceramidosome-mediated necroptosis by shRNA-mediated NMIIA knockdown in
response to FTY720 in lung cancer cells. However, whether ceramidosomes were formed
in other cell types without any external stress stimuli were unknown.
To address this, we used D. melanogaster as a model organism, specifically
ovaries as they contain multiple types of cells at various stages of development. The data
suggested that ceramidosomes formed in germline stem cells, and that inhibition of
ceramidosome formation using siRNA-mediated knockdown of zipper stunted ovary
development potentially by inhibition of germline stem cell signaling without affecting
their survival. Our data suggested that ceramidosomes can also form without any external
stress stimuli, at least in the early stages of oogenesis, selectively in the germline stem
cells in D. melanogaster. A limitation for this study however, is that there is no true
orthologue of RIPK1 in D. melanogaster. RIPK1, closest “relative” in D. melanogaster is
imd

195

, which functions in inflammation signaling similarly to mammalian RIPK1,

however, imd only has a death domain, which we have previously found

65

and have

confirmed in the experiments described in this thesis, dispensable in FTY720-induced
necroptosis. There could be other protein (s) in D. melanogaster that could serve a similar
role to RIPK1 in ceramidosomes formation, but this remains to be investigated.
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Inhibition of ceramide synthesis or knockdown of NMIIA (zipper) limited
ceramidosome formation and ovary development, suggesting important roles for
ceramidosomes in germline stem cells signaling during oogenesis.
Although we have shown the presence of ceramidosomes in D. melanogaster
ovaries, the mechanisms by which ceramidosomes regulate oogenesis are unknown and
need to be determined. It is known that there are nanotubes in the D. melanogaster testes,
which mediate niche stem cell signaling 196. It remains unknown whether ceramidosomes
play similar roles in ovaries. It is possible that ceramidosomes might play a role in the
regulation of germ line stem cell niche organization by enhancing EGFR signaling, as
demonstrated previously by the involvement of nuclear pores and lamina 197, 198.
Thus, this thesis presents a novel lipid-multiprotein complex, involving ceramideRIPK1 and NMIIA complex, which is trafficked to the membrane to form pores,
ceramidosomes, inducing membrane rupture and necroptosis in response to FTY720 in
lung cancer cells, or in germline stem cell signaling de novo regulating oogenesis.
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FUTURE DIRECTIONS
In our previous study, we found that FTY720 induced a non-canonical type of
necroptosis that was independent of RIPK3 and MLKL. This begged the question of the
downstream targets of RIPK1 in FTY720-induced necroptosis. With knowledge from
literature indicating ceramide’s ability to form membrane pores and FTY720 ability to
modulate ceramide signaling in cells we pursued this possibility in necroptosis. In this
study, we have focused on the effects of FTY720 on ceramide generation and localization
during necroptosis. Our studies have elucidated that in small cell (SCLC) and non-small
cell lung cancer (NSCLC) cell lines, FTY720 does not significantly affect ceramide
generation but does induce the formation of ceramidosomes, as discussed earlier.
Although the findings of this study are novel and answer important questions about
FTY720-induced necroptosis in lung cancer, there are still some unanswered questions
that could be investigated in future research.
We also showed, in our initial studies, that PP2A activation mediated cell death
was mitigated by RIPK1 knockdown

65

, this indicated that RIPK1 acted downstream of

PP2A activation. Although this dissertation study explores what occurs downstream of
RIPK1, the mechanisms of exactly how PP2A activates RIPK1 remain elusive. Our
preliminary proximity ligation assay (PLA) studies show that there is a significant
increase in the association between PP2A and RIPK1 in response to FTY720, however,
whether this association is direct binding, and whether PP2A dephosphorylation of
RIPK1 mediates its non-canonical necroptotic activity remains unknown.
In this study, we have also demonstrated the novel role of NMIIA in trafficking
ceramidosomes to the plasma membrane and how critical this role is in mediating cell
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death. However, there remain myriad unanswered questions about NMIIA activation
during FTY720-induced necroptosis. In our other unpublished data, we have also found
out that NMIIA is a target of PP2A. This, we observe by proximity ligation studies which
show increased PP2A and NMIIA association, as well as SILAC mass spectrometry
studies. These findings bring about more questions about exactly how PP2A modulates
NMIIA and how this affects NMIIA role in ceramidosomes trafficking and necroptosis.
Additionally, this brings about the main question, of how PP2A activates both
NMIIA and RIPK1 to induce necroptosis. Different possibilities could be investigated
here; 1) Does PP2A dephosphorylate RIPK1? Is RIPK1 a direct target of PP2A? 2)Is
PP2A indirectly activating RIPK1 via NMIIA? And if so, how is this occurring and
which residues on NMIIA are dephosphorylated by PP2A. Answers to these intriguing
questions will allow for better understanding of this mechanism and this could be
manipulated to affect necroptosis in cancer cells versus non-cancerous cells.
Moreover, we have shown the varying responses of different cell lines to the same
concentration of FTY720. Further studies could be carried out to find out the mechanism
behind the different sensitivities among the cell lines. In our preliminary studies to
investigate this, we examined the proteins that could bind FTY720 to either enhance or
lessen its potency in the different cell lines, hence leading to the different responses to the
same dose of FTY720. To study this, we treated A549 and H1341 cells with biotintagged FTY720, lysed the cells pulled down the FTY720-bound proteins with
streptavidin-coated agarose beads and run the samples on a gradient polyacrylamide gel.
The gel was then stained with coomassie blue dye. We observed one band that was more
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prominent in H1341 cells treated with Biotin FTY720 (Figure 39 A) compared to A549
cells. This band was excised and analyzed by mass spectrometry.
Interestingly, we found that in H1341 cells, compared to A549 cells, Biotin
tagged FTY720 bound to caldesmon, a protein known to inhibit myosin-actin interaction
in cells (Figure 39 B). FTY720 binding caldesmon could be enhancing NMIIA
movement along actin filaments (by inhibiting the inhibitor), to promote more
ceramidosomes on the plasma membrane and more cell death, hence making these cells
more sensitive to FTY720 compared to A549 cells. This experiment could be confirmed
and further investigated to better understand why this phenomenon is occurring in one
cell line and not the other. Answers to these questions will have clinical relevance as they
could potentially predict which type of cancer would respond more ceramidosomeinducing, necroptotic triggering chemotherapeutic agents.
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Figure 39 : Biotin-FTY720 binds caldesmon in H1341 cells
A. Coomassie blue staining of H1341 and A549 cells (treated with BiotinFTY720/Biotin) after IP with avidin-coated beads. B. Expression of caldesmon, one of
the proteins identified from mass spectrometry analysis of the band indicated by the black
arrow in A, in H1341 and A549 after IP with avidin-coated beads. C. Expression of
caldesmon in H1341 and A549 cells without FTY720 treatment
In our studies, we have seen that ceramidosomes were only evident in cancer cell
lines and not in non-cancer cell lines that we looked at. This lack of ceramidosomes
formation in these cell lines also correlated with their response to FTY720. Cells that did
not form ceramidosomes also required a lot more FTY720, almost twice as much to
induce cell death. We still do not why non-cancerous cells did not form ceramidosomes
in response to FTY720. This intriguing phenomenon in cells could be further investigated
to understand the implications of this phenomenon in future cancer treatment. Could
making normal cells more resistant to ceramidosomes formation reduce the side-effects
typically seen in patients undergoing chemotherapy?
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Our study showed us that ceramidosomes formed large membrane pores and
appeared to be highly organized and well structured. Because of this and ceramide’s
implication in stem cells differentiation and development in non-pathological conditions
130, 131

, we decided to investigate whether ceramidosomes were also formed in

physiological condition without FTY720 exposure or any exogenous stress stimuli. To
determine this, we elected to use D. melanogaster ovaries due to the presence of various
stages of developmental process and stem cell types

149, 199, 200

. We isolated ovary tissues

from D. melanogaster and performed immunofluorescence using anti-ceramide and a
germline stem cell marker, 1B1 201. Interestingly, ceramide-enriched macrodomains were
detected colocalized with the germline stem cell marker (Figure 40 A), which also marks
structures in the germline stem cells known as spectrosomes/fusomes

202

, known to be

key in synchronizing germline stem cells differentiation by sharing of intracellular
contents.
To further examine the role of ceramide membrane pores/macrodomains in the
ovary development, we analyzed the effects of the inhibition of ceramide synthesis using
fumonisin B1 (FB1) on the formation of ceramide-enriched macrodomains and ovary
development. the data showed significant decrease in ceramide and 1B1 co-localization
without affecting the survival of GSC (Figure 40 B-C), indicating a possible key role of
ceramide in GSC signaling.
To determine if ceramidosome play any functional roles in the ovary
development, we obtained zipper (NMIIA homologue)
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RNAi flies and drove RNAi

using Nos RNAi driver. We then determined the effects of zipper knockdown on the
formation of ceramide pores/macrodomains and ovary development. Remarkably,
101

siRNA-mediated knockdown of zipper inhibited the formation of ceramide-enriched
macrodomains in ovaries, and resulted in a defective ovary development in insects,
leading to a sterile phenotype (Figure 41 A-B). Overall, these data suggest that
ceramidosome, at least containing ceramide and NMIIA homologue zipper, are possibly
formed de novo without any external drug treatment or stress stimuli selectively in GSC
found in the early developmental stages of ovaries. We suggest that ceramidosomes could
be playing a key role in oogenesis at least in D. melanogaster.
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Figure 40 : Ceramide colocalizes with germline stem cell marker in D. melanogaster
ovaries and this is inhibited by FB1
A. Isolated ovarioles from D. melanogaster were stained for ceramide and stem cell
marker (1B1) using the respective antibodies. The rightmost panel shows a zoomed-out
picture of the framed area. B. Isolated ovaries from D. melanogaster exposed to FB1
(100 µM)/Vehicle were stained for ceramide and 1B1. There was decreased colocalization between ceramide and 1B1 in the flies exposed to FB1 the rightmost panels
show zoomed-out pictures of the framed areas. Quantification of 1B1 and ceramide
colocalization is shown in C.
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Figure 41 : Knocking down NMIIA (zipper) in D. melanogaster leads to a sterile
phenotype
A. To investigate the effect of genetic loss of zipper (NMIIA), ovarioles isolated from
zipper RNAi flies were stained for ceramide and stem cell marker (1B1). A. shows zipper
RNAi flies had stunted ovary development compared to Nos.Luciferase RNAi (control).
B. shows 1B1 and ceramide staining in the germarium in Nos.Luciferase ovarioles (top
panel) compared to the whole ovary in the Nos.zipper RNAi flies (bottom panel).
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Given that ceramidosomes (identified by ceramide antibody) were colocalized in
with spectrosomes/fusomes in germlines stem cells and knocking down a key component
of ceramidosomes led to defective ovary development, our data suggest that
ceramidosomes could be involved in the trafficking of non-polar molecules like sterols
between cells, especially germline stem cells during the early stages of oogenesis.
However, further studies to understand if this is what is going on, need to be carried out.
As before-mentioned, FTY720 is currently being used to treat multipole sclerosis.
Compared to this role, the dose required to induce cancer cell death is quite high
compared to the dose typically required to induce immune suppression in MS.
Predictably, the side effects for this would be deleterious to cancer patients. This
necessitates the need for analogues of FTY720 that are more potent at lower does than
FTY720 and possibly have less side-effects. Additionally, non-phosphorylatable
analogues of FTY720 would be more clinically relevant for cancer treatment as they will
induce tumor suppression without the immune suppression driven by P-FTY720.
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Appendix
Inorganic Phosphates (Pi) Analysis
Day 1
**make Ashing buffer 9:1:40 (10N H2SO4: 70% HClO4: H2O) (make a lot to keep at
bench for future use)
**Make 10mM NaH2PO4 if you don’t have this already (make a lot to keep at bench for
future use)
Protocol
Add 1 mL chloroform and 2 mL methanol, vortex
Add 800µl ddH2O, vortex
Add 1 mL chloroform, vortex
Add 1 mL ddH2O vortex
Spin 3000 rpm 5 minutes
** in the mean-time take fresh glass tubes (duplicates for each sample) and label them
Using glass pipet, insert into bottom clear phase and take 1 mL, divide into two tubes (0.5
mL each tube)
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Dry under nitrogen. (turn top knob; silver (just until it’s on), then front knob to
approximately 100 KPa. Insert pipets in tubes dry completely
** in the meantime, make standards with NaH2PO4
Stock solution to keep at the bench is 10 mM
For standards, dilute and aliquot of 10 mM to make 1 mM and then dilute the 1mM to
make 0.1mM. Use the 1mM and 0.1mM stock solutions to make standards
Follow table below:
Concentration (in nmoles)
0
1
3
5
10
20
40
60
80

Volume from stock (in µl)
n/a
10
30
50
10
20
40
60
80

Stock solution
n/a
0.1mM
0.1mM
0.1mM
1mM
1mM
1mM
1mM
1mM

Add 600 µl ashing buffer to samples and standards, vortex well
Put samples in cold heating block in the hood, then set it to 160°C for O/N (16-24 hrs)

Day 2
Prepare fresh ascorbic acid (9%) and ammonium molybdate (0.9%)
**1.8 g Ascorbic acid in 20 mL ddH2O
**225 mg ammonium molybdate in 25 mL
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Turn on water bath 45°C
Add 0.9 mL ddH2O, vortex well
Add 500 µl 0.9% ammonium molybdate, vortex well
Add 200µl 9% ascorbic acid, vortex
Incubate in water bath at 45°C for 30 minutes (check every 10 minutes for color
development, if purple color develops before the 30 minutes, take the samples out of the
water bath)
Add 200µl of each sample and standard per well in a 96 well plate and read at 600 nm
**To calculate amount of phosphates from the colorimetric readings, make linear curve
from the standards, using the equation, plug and chug. The value you get, multiple by 4
then again by 4 if you received 1mL dried lipids from the core.
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